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Abstract 
 
In Palestine, there are no studies carried out for effective dose (ED) assessment in abdominal-
pelvis CT scan and verify whether it carries excessive radiation or not. Excessive dose means 
more cancer risk or other adverse health effects may be attributed to excessive radiation dose 
in CT-examinations. 
 
CT scanners are the highest source of radiation that patients are exposed to during the 
diagnosis of their illness. Abdominal-pelvis CT scanning typically provides an ED of nearly 
10 mSv where this value is considered normal worldwide. This dose is equivalent to ~ 400 
Posterio-Anterior (PA) chest X-ray radiation dose. Therefore, there is a need to assess the 
effective dose and lifetime cancer risk values (by using BEIR VII report), during all CT scans 
in Palestine in order to protect patients' safety.  
 
The main objective of this study is to estimate the radiation effective dose and lifetime cancer 
risk to adult patients (18-80 years old) undergoing abdominal-pelvis CT in the chosen 
governmental and private hospitals in the West Bank. A quantitative cohort retrospective 
design was used to achieve this objective. All adult patients (18– 80 years old) underwent 
abdominal-pelvis CT examinations in the chosen six governmental and private hospitals in the 
West Bank. Data collection was through CT-scanner monitors reports issued during two 
months in the selected hospitals.  
 
Average effective dose was 11.8 ± 5.3 mSv for the total study population ranged between 0.5 
mSv and 36.79 mSv. While LAR of cancer risk incidence was 0.082 % (1 in 2116), and LAR 
of cancer risk Mortality was 0.049 % (1 in 3164) which is considered in low level of cancer 
risk. 
 
 In sectors, average effective dose was 11.45 ± 6.4 mSv for private ranged between 1.77 mSv 
and 36.79 mSv, and 12.16 ± 4.1 mSv for governmental ranged between 0.5 mSv and 25.2 
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mSv. Based on hospitals, the highest average EDs values in mSv, were in R.H with (16.41 ± 
7.2) mSv, and the lowest one was A.H (7.93 ± 3.7) mSv. 
 
Whereas the highest LAR cancer risk incidence was in R.H with 0.122% (1 in 1187) and the 
lowest one was A.H 0.050 % (1 in 2602). The highest LAR cancer risk Mortality was in R.H 
with 0.071% (1 in 1856), and the lowest one was A.H 0.031% (1 in 4061). 
 
Average effective dose for adult patients who underwent abdominal-pelvis CT examinations 
in this work was in acceptable level. LAR of cancer risk Incidence and Mortality were all in 
low level. 
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Chapter One 
 
 
Introduction 
 
This chapter gives the background, problem statement, justification, study aim and objectives, 
hypothesis and research question. 
 
1.1 Historical Background 
 
X-ray is a high energy electromagnetic radiation. It was discovered by William Rontgen in 
1895. It consists of ionizing x-ray photons, which can penetrate human body to provide 
images, and can often be used instead of surgery, which was used previously for medical 
diagnosis, while diagnostic surgery was associated with a lot of pain and risks for patient. X-
ray machines are in widely used and developing continuously. 
 
Computed tomography (CT) imaging was invented in 1970’s. It consists of a rotating X-ray 
tube and detectors combined with a computer to process and produce a cross-sectional and 
three dimensional images of all body tissues quickly. It produces a high quality and resolution 
CT-images, and has the ability to cover a large area of the patient’s body. CT imaging can take 
accurate images of heart and blood vessels, small and large tumors (can determine the 
presence, location, and size accurately) (Muhogora et al., 2009).  
 
The number of scanners is dramatically increasing with continuous and wide improvements in 
quality, accuracy, speed and resolution. Therefore, the number of CT examinations has 
increased to reach millions of CT exams yearly worldwide, which means increasing the 
amount of ionizing radiation (i.e. increasing patient absorbed dose and total population dose). 
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CT-Scan is considered to be the highest contributor to the total population dose, with more 
than 60 million CT-scans obtained in U.S. annually (Martin and Semelka, 2006). In 2006, CT 
was responsible for 70% of medical radiation exposure (Martin and Semelka, 2006), CT-dose 
has a potential future or lifetime cancer risks, since ionizing X-ray beam can cause DNA 
damaging and mutations of cells, which then may grow to form tumors (Storrs, 2017). 
Therefore, dose from CT examinations became a global public health issue. 
 
The potential radiation effects and risks on human body are attributed to the absorbed dose 
levels in CT examinations. Diagnostic Reference Levels (DRLs) and specific European 
Guidelines on quality criteria were established and distributed globally for CT-procedures 
dose optimization and assessment (International Atomic Energy Agency, 2013). These 
guidelines aimed to insure that all CT doses are within the acceptable ranges for each 
examination which allows estimating the possibility of stochastic and deterministic effects of 
radiation exposure. Any increase in the absorbed dose will increase the potential changes in 
cells growth and DNA composition (cancer risk) by ionizing radiation. The effective Dose 
(ED: describe the amount of radiation received, the magnitude of ED is related to the 
stochastic radiation risks of cancer induction and the production of genetic effects) (ICRP, 
1990; ICRP, 1977), is the mostly used and preferred as a CT-dose descriptor, and for radiation 
quantization and determination of the potential risks. 
 
Recently, both public and governmental health sectors have realized that the radiation 
exposure from CT is a public health issue. There is a great interest worldwide from researchers 
on this issue. Epidemiological studies focus on the relationship between patient’s absorbed 
dose and cancer risk. 
 
In this study, radiation doses to patients, from routine abdominal and pelvis CT procedures, 
will be estimated using equations. The aim is to determine radiation effective dose received by 
adult patients with ages ranging from 18 to 80 years, in order to protect patients undergoing 
CT-examinations from excessive radiation absorbed dose, and to serve as a dose guideline to 
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provide more awareness about CT-overdose for radiologist and radiographers and other 
related medical staff.  
 
1.2 Problem statement 
 
Computerized Tomography (CT) became a highly requested procedure in medical imaging 
departments because of its ability to provide high detailed fast images. In radiation protection, 
the risk of adverse health effects is proportional to the amount of radiation-absorbed dose, as 
previously mentioned. The amount of dose depends on the type of medical imaging modality 
and amount of X-ray in the examination. Abdomen and pelvis CT has an adult’s approximate 
effective radiation dose (ED) of 10 millisievert (mSv); which is a measurement of the energy 
absorbed by body tissues (RI.org, 2016). This is equivalent to ~400 Posterio-Anterior (PA) 
chest X-ray in comparison to natural background radiation for three years (RI.org, 2016). 
However, any increase in this average will be associated with an increase in the possibility of 
fatal cancer in the future. 
 
In 2005, National Academy of Science report showed that one patient in 1000 develops cancer 
from exposure to a 10 mSv dose of radiation (NAS, 2005). Lack of awareness among 
physicians, radiologist, radiographers, and patients is causing an increase in the lifetime cancer 
risk.    
 
Any small increase in the effective dose will increase cancer risk probability. This is a 
worldwide public health concern nowadays. Large numbers of population undergo CT scans 
daily. This encourages further epidemiological studies and researches in this field. 
 
Whereas, ionizing radiation exposure from medical imaging examinations for diagnosis has an 
adverse health effects divide to deterministic health effects because of cell death or damage by 
ionizing radiation dose as hair loss and erthema. There are also stochastic health effects, such 
as lifetime cancer risk because of mutations (Schmidt, Hupfer, Saltybaeva, Kolditz & 
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Kalender, 2017). ED is not a measurement, but instead of that it reflects the stochastic risk 
such as cancer induction due to ionizing radiation exposure. EDs facilitates biological effects 
comparisons between different types of medical diagnostic procedures to be used in a 
mathematical model for lifetime cancer risk incidence and mortality calculations (McCollough 
et al., 2009). 
 
Risks of radiation exposure depend on the value of the effective dose, type of the examination 
and the quantity of radiation that the patient receives, in addition to the age and sex. The 
BEIR VII report (which depending on patient age and sex), was used for EDs and LAR cancer 
risk assessment as shown in Table 1.1(The BEIR VII (2006) report, 2006).  
 
Table 1.1: Approximate lifetime fatal cancer risk for patients from examinations. 
 
Risk level Approximate lifetime fatal cancer risk for adult patients from 
examinations 
Negligible less than 1 in 1 000 000 
Minimal 1 in 1 000 000 to 1 in 100 000 
Very Low 1 in 100 000 to 1 in 10 000 
Low 1 in 10 000 to 1 in 1 000 
Moderate 1 in 1 000 to 1 in 500 
 
1.3 Justification 
 
Availability of radiation doses to patients during CT, allows comparison to be made of the 
hazards in CT-scans with alternative diagnostic examinations, which also use ionizing X-ray 
radiation to obtain images. Additionally, CT-radiation doses can be used to optimize CT 
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protocols with respect to the radiation risk for the patient. Different national surveys proved 
that CT is the largest source of radiation exposure and provides huge percentage of the 
collective dose from medical radiation exposure, nearly 35% in Germany (Kaul et al., 1997), 
and 47% in the UK (Hart and Wall., 2004). 
 
Calculating effective dose helps to improve patient safety in CT-examinations. So EDs 
estimation can be used to assess radiation doses received and to make effective dose 
comparisons between different scanners to check for any differences between different and 
identical scanners. This will help to determine whether such CT radiation doses to patients are 
as low as reasonably achievable (ALARA principle)(Uffmann and Schaefer-Prokop, 2009), as 
required by the International Commission on Radiological Protection (ICRP). 
 
One study reported that CT scans performed in the U.S. in 2007 will result in 29,000 new 
cancer cases and roughly 15,000 deaths that would not have occurred if CT-scan was not 
preformed (Berrington et al., 2009). These risks would increase with each additional CT scan 
a person receives. 
 
The importance of this study comes from being the first in assessing the average CT radiation 
doses for adult patients with ages ranging from 18-80 years undergoing routine abdominal-
pelvis CT. The ED will be used to assess radiation exposure amount and lifetime cancer risk 
incidence and mortality for those patients. While there is a global trends globally towards 
trying to decrease the number of CT scans, in Palestine CT examinations were increasing 
rapidly from 42,818 in 2013 (MOH, 2013), to 70,599 in 2014 (MOH, 2014)  and 88,191 in 
2015 (MOH, 2015). 
 
1.4 Study Goal 
 
To estimate the radiation effective dose and lifetime cancer risk to adult patients (18-80 years 
old) undergoing abdominal-pelvis CT in governmental and private hospitals in the West Bank. 
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1.5 Study Objectives  
 
1.5.1. General objective:  
To estimate the effective dose and lifetime cancer risk of abdominal-pelvis CT for adult 
patients (ranging from 18 to 80 years). 
  
1.5.2. Specific objectives: 
1. To record frequency of abdominal-pelvis CT examinations during study period. 
2. To assess collective average effective dose from abdominal-pelvis CT per hospital. 
3. To assess collective effective doses contribution of each scanner to the total collective 
effective doses from CT-procedures. 
4. To compare total effective dose between different and identical CT scanner models. 
5. To develop criteria for determining the limits that are clinically acceptable and to determine 
which models are more suitable and acceptable for clinical use to improve patient’s safety 
and protection. 
6. To increase the awareness of medical staff (radiologist, radiographer and physicians) 
regarding high dose risk of cancer probability in abdominal-pelvis CT generally, and more 
specifically on colon. 
 
1.6 Study Hypothesis 
 
The differences between average effective doses (EDs) evaluated in Palestine and 
internationally used will be within acceptable limits. 
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1.7 Research Question 
 
- Are the average effective doses (EDs) within acceptable limits and are they safe as compared 
to international ones? 
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Chapter Two 
 
 
Literature Review 
 
This chapter reviews some literature, published studies and researches on CT-dose assessment 
and related risk, and display different methodologies that were used to determine dose and 
related cancer risk assessment. 
 
2.1 Introduction 
 
In an article entitled (Computed Tomography (CT) Scans and Cancer), from National Cancer 
Institute, the author concluded that ionizing radiation exposure increase the risk of cancer from 
CT-Examinations more than that from other conventional X-ray examination such as,  routine 
X-ray and mammography, which use very low levels of ionizing radiation, compared with that 
from CT exposure. However, sometimes having CT is much more useful than the 
conventional X-ray, especially if it is used for cancer diagnosis or other serious conditions 
(Cancer.gov, 2013). 
 
Commonly, the extra risk to develop a fatal cancer from CT examination is nearly 1 per 2000 
(U.S FDA., 2009). While the risk of death from cancer among the U.S population normally is 
nearly 1 per 5 (Howlader et al., 2013). In the same article, the author concluded that global use 
of CT and other diagnostic procedures that use ionizing radiation to provide images of 
patient’s body, has increased the risk in getting cancers, and that could lead to huge numbers 
of cancer cases in the future (Berrington et al., 2009; Smith-Bindman et al., 2009). 
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In a study that aims at assessing the awareness among patients who had abdominal or flank 
pain and who underwent CT-examination in Emergency Department, about the benefits and 
risks of CT-dose and if that had been interpreted previously, and also they were then asked to 
estimate CT-dose compared to radiation dose from plain chest X-ray. Emergency doctors 
(who often request CT-examinations), and radiologists (who write and interpret CT-scans) are 
included in the survey of the previous study (Lee et al., 2004).  
 
In the same study, only 3% of patients and 9% of emergency doctors had the knowledge that 
CT-dose raised cancer-lifetime risk. Surprisingly, only 47% of radiologists in the survey 
provide the correct answer for radiation cancer risk. In radiation dose estimation of CT 
compared with plain chest X-ray, mostly, they believed CT provided radiation dose ranging 
from 2 to 10 times of that in chest X-ray. Unexpectedly, 64% of patients, 44% of eemergency 
doctors, and 56% of radiologists chose this answer from five options.  
 
However, in reality, CT-dose is nearly 100-250 times more than a chest X-ray dose. Only 22% 
of the emergency doctors and 13% of radiologists provided a right answer (none of the 
patients knew that it is high). Patients were not educated about this issue. Since 78% of the 
emergency doctors said that, they had not mentioned or interpreted CT examination risks and 
benefits to patients. Around (93%) of patients answered that CT scans’ risks and benefits had 
not been informed to them previously (Lee et al., 2004).
 
 
American College of Radiology (ACR) has also developed and facilitated the (Dose Index 
Registry) which contains information related to dose provisions for all CT examinations at all 
participating centers and hospitals. The data in the registry are then used to compare CT dose 
indicators in those centers and hospitals and to produce national benchmarks. Finally, it was 
mentioned that CT manufacturers are developing newer systems that can produce images 
higher in quality by using much lower X-ray radiation dose (acr.org, 2013). 
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2.2 Previous studies 
 
2.2.1. Local and regional studies: 
There are few studies in Palestine pertaining to the CT effective dose for patients in hospitals 
with CT scanners and its role in causing cancer. However, there is a non made on abdominal-
pelvis CT-scan protocols. 
 
In a very recent local study entitled “Breast Radiation Doses and Cancer Risk from Female 
Chest Scans in Palestine”, author mentioned that there are nearly 28 scanners in Palestine, 24 
scanners in West Bank, and only 4 scanners in Gaza Strip. Study included 10 Palestinian 
hospitals in Palestine (200 female patients underwent chest X-ray in these hospitals). 
 
For the total study population, the mean ED was 7 mSv, values ranged between 3 to 14.7 mSv, 
the mean ED for breast was 15 mSv and ranged between 6.5 and 17.5 mSv.  
 
The Lifetime attributable breast cancer risk was also estimated to be 0.00014 % in younger 
female or 1 in 2645 for 15-39 years, and 0.00014 % in older female or 1 in 10473 for 40 to 60 
years. While ICRP dose shouldn’t exceed 45 mGy, and LAR of breast cancer for younger and 
older female patients shouldn’t be higher than 0.00865% and 0.00160 % respectively. Author 
found that ED to glandular breast tissue declines with using suitable exposure scanning 
parameters (Kameel, 2017).  
 
2.2.2. International studies: 
Many epidemiological studies were carried out globally and focused on identifying, assessing 
and controlling the radiation absorbed doses. Those studies estimated effective dose of CT 
examinations and its contribution in each examination.  
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In a study, (Trends in examination frequency and collective effective doses from computed 
tomography (CT) procedures in Sudan), abdomen CT accounted for the highest number of 
population. Number of patients who underwent abdominal CT were 457 patients; with an 
average effective dose of 7.01 mSv ranging (1-24.4 mSv). While patients who underwent 
pelvis CT were, only 30 patients had an average ED of 4.82 mSv ranging from 1.44-11.23. In 
Chest CT, 263 patients with an average ED of 4.45 mSv ranges (1.28-11.45), then head CT 
with 118 patients had an average ED of 2.04 mSv ranging (0.2-4.41), and neck CT with only 
21 patients with an average ED of 2.58 mSv ranging (1.27-4.96) (Elameen, 2010). 
 
In the same study, it can be noted that abdomen CT occupied the highest ED with 32% in 
percentage. The author attributed that to the high ED per examination resulted from abdomen 
CT, while abdomen, Lumbo-Sacral Spine (L.S.S), and pelvis CT were equal in ED per 
examination (6.6 mSv), then head with 5.3 mSv, and chest 4.6 mSv. ED dose for abdomen CT 
was within acceptable range in this study.  
 
The study also showed comparisons of EDs per examination for Norway, UK, and Sudan, 
where abdomen CT ED were 12.8, 10, 6.6 mSv, and for L.S.S CT were 4.5, 8, 6.6 mSv, while 
for head were 2, 2, 1.6 mSv, respectively. Therefore, we notice that abdomen occupied the 
highest ED level in all countries and examinations with slight differences (Elameen, 2010). 
 
In another article entitled (An estimation of the annual effective dose (AED) to the Canadian 
population from medical CT examinations), results showed that the ED from CT-examinations 
was 0.74 mSv in 2006, while in 1991, it was only 0.19 mSv. This marked increase in CT-dose 
was attributed to the introduction of the multi-detector CT-scanners where CT examinations 
rate and higher dose for each examination were doubled (Chen and Moir, 2010). 
 
This study also showed that percentage of patients receiving repeated abdominal CT scans was 
70 % with an annual effective dose (AED) of 10 mSv. Single repeat percentage for abdominal 
CT was 17.6% with AED of 30 mSv. It was finally concluded that for three or more repeated 
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times, the percentage was 5.7% with AED of more than 40 mSv. This is equivalent to nearly 
129 years of cosmic rays exposure, or to 35 years of the average radon exposure concentration 
in Canadian houses.  
 
In an article entitled (Optimization of patient Dose in Abdominal Computerized Tomography), 
CT-dose optimizations was achieved by CT- scan protocol and improvement of the referring 
criteria.  
 
Software from National Radiological Protection Board (NRPB) was employed for EDs 
estimation. Mean age of patients was 45.4 ±18 years, average ED was 13.5 before the CT-dose 
optimization, and reduced to be 4.3 mSv after optimization. Therefore, dose optimization 
protocol in this study successfully decreased the average ED to 31.9 % (Elnour and Sulieman, 
2011). 
 
In another article entitled  “Radiation Effective Doses to patients undergoing abdominal CT 
examinations”, mean values of patient ED were 6.1 mSv ± 1.4 for children (included 31 
patients aged 10 years and less), 4.4 mSv ± 1.0 for young adults (included 32 aged 11-18 
years), and 3.9 mSv ± 1.1for adult patients (included 36 patients older than 18 years).  
 
The author also showed that energy imparted values to patients undergoing abdomen CT-scan 
had a factor of three times more in adult patients than in children, but the corresponding 
patient EDs were 50 % much more in children than in adult patients (Dan et al., 1999). 
 
In a retrospective cross-sectional study entitled (Radiation Dose Associated with Common 
Computed Tomography Examinations and the Associated Lifetime Attributable Risk of 
Cancer), aimed to describe the radiation dose and to assess the lifetime attributable cancer 
risks by these doses measurements in the 11 most popular CT examinations, was performed on 
1119 consecutive adult patients during 5 months in 2008.  
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There was a significant variation between different CT examinations, the average ED for head 
CT was 2.1 mSv, ranged between 1.8 and 2.8 mSv, the average ED for a multiphase abdomen 
and pelvis CT was 31 mSv, ranged between 21 and 43 mSv.  
 
While LAR cancer incidence between patients who underwent a coronary angiography CT at 
age 40 from that procedure was (1 in 270 women), (1 in 600 men), in comparison with routine 
head CT LAR of cancer incidence was (1 in 8,100 women at the same age) and (1 in 11, 080 
men). While for 20years old patients, the LAR cancer risks were nearly doubled, and for 60 
years old patients the LAR cancer risks nearly 50% lower. 
 
Authors described the necessity for more standardization between institutions, and requested 
to be sure for the need of CT scan, especially for younger female, in addition to balance CT 
benefits and risks for those patients before perform such examinations (Smith-Bindman, 2009). 
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Chapter Three 
 
 
Theoretical Background 
 
This chapter contains all variables, processes, and outcomes of this study. 
 
3.1Conceptual framework 
 
This study aims to assess the radiation effective dose and lifetime cancer risk to adult patients 
(18-80 years old) undergoing abdominal and pelvis CT in governmental and private hospitals 
in the West Bank, ED will be used as a dose estimator or descriptor. 
 
3.1.1. Independent Variables:  
Independent Variables of this study include: 
 
1. Patient’s examination data: 
      Include Kilo-Voltage peak (kVp), milliAmpere-seconds (mAs), slice thickness (T), Dose 
Length Product (DLP), CT dose index volume (CTDIv). 
 
2. Socio-demographic factors: 
- Gender (Male / Female). 
- Age (18-80 years). 
 
3.1.2. Dependent Variables : 
Dependent Variables (outcomes) of this study include: 
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1. Average ED at each hospital. 
2.  Lifetime cancer risk incidence (LAR Inc %). 
3. Lifetime cancer risk mortality (LAR Mor %). 
 
3.2 CT dose  
 
Effective dose estimation in CT basically depends on radiation exposure factors that include 
kVp , mAs, CTDIv, DLP, and Pitch values.  
 
3.2.1. Kilo-Voltage peak (kVp): 
It is the X-ray photons energy. kVp value directly proportion with radiation absorbed dose 
during CT examination, which means increasing in effective dose value. 
 
3.2.2. milliAmpere-seconds (mAs):  
Is the x-ray tube current milliAmpere (mA) per scan time (s), which is represented the amount 
of radiation X-ray photons per second, the relationship between mAs and patient absorbed 
dose is that 50% reduction of mAs value will be associated with 50% reduction of the 
radiation dose. 
milliAmpere-seconds (mAs) = tube current(mA) X exposure time (s) ………………..…(1) 
 
3.2.3. Pitch Ratio (P): 
Estimate by the table movement (increment distance) per on full rotation of the X-ray tube 
divided by the width of the X-ray beam. There is a reverse relationship between the Pitch 
value and the patient dose, so increase pitch leads to decrease patient dose, and vice versa. 
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3.2.4. Computed Tomography Dose Index volume (CTDIv): 
CTDIv measured in milliGray (mGy), is an estimation of the average dose during the CT scan 
volume to a standardized phantom. 
 
Total amount of delivered radiation to a standardized phantom is equal Dose Length Product 
(DLP) value, which is represented by CTDIv and scan length. CTDIv is introduced to estimate 
the radiation dose in multi-detector scanner and permits different values in exposure in Z-axis 
direction when the pitch is above 1 for one rotation of X-ray tube.  
 
3.2.5. Dose Length Product (DLP): 
It is used in the effective dose estimation for slices series or whole procedure. In some of CT 
scanners, the DLP and CTDIv values appear for each CT examinations.  
 
DLP represents the whole energy amount that is delivered by a given CT examination, which 
represents in equation number 1:  
 
DLP (mGy.cm) = CTDIv (mGy) X Scan Length (cm)…………………………………… (2) 
 
DLP depends on the converge imaged area length of the patient body during CT scan, so that 
means any increase in DLP directly means increase in the effective dose value.  
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Chapter Four 
 
Methodology 
 
This chapter provides experimental framework of the study, from data collection, to the 
calculations of effective dose and assessment of lifetime cancer risk, data analysis and 
comparison.  
 
4.1 Introduction 
 
This study aims to assess the value of the effective dose and the lifetime attributable risk (LAR) 
of cancer incidence and cancer mortality from abdominal-pelvis CT-examinations protocols. 
Required data was taken from CT scan registries in all radiological departments in the chosen 
governmental and private hospitals in West Bank. Abdominal-pelvis CT scans carried out 
within two months period were collected.  
 
4.2 Settings 
 
The study was conducted at chosen governmental and private hospitals that have CT-unit in 
the West Bank. Governmental hospitals include (Jenin Governmental Hospital, Princess Alia 
Hospital, Palestine Medical Complex), which provide health services free or semi-free (health 
insurance), so they have the largest load on CT-examinations, and has become the main source 
of abdominal-pelvis CT examinations when compared with other private or chargeable 
hospitals. We also included private hospitals which have the largest load on CT-examinations; 
(AL-Razi Hospital, Arab Istishari Hospital, AL-Ahli Hospital). Results are used to compare 
the results between the two sectors (governmental and private), and to investigate reasons for 
the differences in ED, and to estimate lifetime cancer risk, if any. 
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4.3 Research design 
 
Quantitative retrospective cohort study was chosen to fulfill the aim of the study. Data was 
obtained from two months records before the beginning of data collection from included 
radiological departments of the chosen governmental and private hospitals in the West Bank.   
 
4.4 Study Population 
 
Study population includes all adult patients with ages ranging from 18 to 80 years, undergoing 
routine abdominal-pelvis CT examinations in the West Bank. 
 
4.5 Study Sample 
 
Multistage sampling methodology was adopted. The West Bank is divided into three regions 
(First Stage) which are; northern region (Tulkarem, Qalqylia, Jenin, Nablus, Tubas and Salfit), 
middle region (Jerusalem, Ramallah and Jericho) and southern region (Hebron and 
Bethlehem).  
 
Two major hospitals were selected in each region (One governmental and one private) which 
represents the second stage. Then, all adult patient files that are in the inclusion criteria and 
undergone routine abdominal and pelvis CT examinations, between Novembers to December 
2016 in the selected hospitals, were included in the study. 
 
o Northern region:  
 Jenin Governmental Hospital and AL-Razi Private Hospital. 
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o Middle region:  
 Palestine Medical Complex (Governmental hospital) and Arab Istishari private 
Hospital. 
 
o Southern region:  
 Hebron Governmental Hospital and AL-Ahli Private Hospital (Patient’s friends 
society). 
 
4.5.1. Inclusion criteria: 
All adult patients ranging from 18 to 80 years who underwent routine abdominal-pelvis CT 
examinations in the chosen governmental and private hospitals in the West Bank, during two 
months between Novembers to December 2016, were included. 
 
4.5.2. Exclusion criteria: 
Patients with gross abnormalities and those who will need procedures involving special details 
or additional body parts were excluded. 
 
4.6 Study tool  
 
Study tool used to assess effective dose and lifetime cancer risk contained two parts: 
 
4.6.1. Patient's file: 
Data about Patient’s age and sex, slice thickness, filter type, and DLP, CTDIv and/or CTDIw, 
were extracted from patients file for each participant in the study. 
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4.6.2. Global equations:  
Global equations were used for radiation dose and lifetime cancer risk assessment. Equations 
were used as dosimeter tool for quantifying CT doses, and improving patient protection 
(reduce any attributed risk of overdose).  
 
This study is directed to radiologists, radiographers, medical physicists, CT scanner 
manufacturers and related medical researchers. It permits radiation professionals to take very 
accurate CT images with much more patient safety from any associated risks of overdose. 
 
4.6.3. The BEIR VII report: 
The most current and recent model for cancer risk assessment and other health risks from low 
level ionizing radiation exposure. It is the first model of its kind that provide detailed 
estimation of lifetime cancer risk incidence and mortality, basically this report for cancer risk 
assessment depends on epidemiological studies, and on the population from Hiroshima and 
Nagasaki in 1950, whom were residents, popular as the life span study (LSS).  
 
This report can estimate cancer risk for leukemia and other non-leukemia cancers. The 
radiogenic cancer risk is related to the age and sex of exposed patient and radiation linear 
energy transfer. The latency periods by this report were ten years for other leukemia cancers, 
and two years for leukemia. 
 
4.7 Data collection 
 
Data were collected by using a work sheet for all adult patients who underwent abdominal-
pelvis CT in the included hospitals during study period to insure the consistency of the data 
(APPENDIX A and B). This stage was performed in three main steps: 
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4.7.1. Patient’s data collection: 
Patient’s data and factors used for ED and LAR assessment include Patient’s sex, age, kVp, 
mAs, slice thickness, scanning length, and CTDIw and/or CTDIv. Data was filled in specified 
self-designed worksheets, for more accuracy and consistency. 
 
4.7.2. Comparison between CT-scanners: 
 
Six CT-scanners were included to estimate EDs and LAR during this study. These scanners 
are installed in six private and governmental hospitals radiological departments. Table 6.9 
shows six CT scanners specifications in West Bank. 
 
Table 4.1: Specifications of CT scanners that used in included hospitals. 
 
Hospital Sector Manufacturer/ 
Installation year 
Scanner Model 
P.A.H Governmental Philips Medical 
systems, 2010. 
16 slices, 
 
J.G.H Governmental GE Medical systems, 
2008. 
4 slices, 
 
P.M.C Governmental Philips Medical 
systems, 2010. 
64 slices 
 
A.I.H Private Philips Medical 
systems, 2014. 
128 slices 
A.H Private GE Medical systems, 
2014. 
128 slices 
R.H Private Philips Medical 
systems, 2016. 
128 slices, 
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217; 50% 218; 50% 
Private
Governmental
4.7.3. Distribution of abdominal-pelvis CT scans: 
4.7.3.1 Distribution of abdominal-pelvis CT scans per sector: 
 
Total study population was distributed in two sectors (private and governmental), each 
consisted of three hospitals, total patient number in both sectors was 435, since private sector  
included 217 adult patients (50%), and governmental sector  included 218 adult patients (also 
50%), which are shown in Figure 4.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Frequency of abdominal and pelvis CT-examinations per sector. 
 
4.7.3.2. Distribution of abdominal-pelvis CT scans per hospital: 
 
The distribution of abdominal-pelvis CT examinations, which were performed at included 
hospitals for the period of study, is shown in Figure 5.5. ED and LAR assessment were 
performed for adult patients (18-80).  
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A total number of 435 adult abdominal-pelvis CT examinations were recorded from the CT-
unit. Out of them, 230 (53%) were males and 205 (47%) were females they underwent 
abdominal and pelvis CT-scans in six hospitals, the highest being in Princess Alia Hospital 
(P.A.H) with 156 patients (36%) followed by AL-Ahli hospital (A.H) 104 (24%) and Arab 
Istshari Hospital (A.I.H) 90 (21%), Jenin Governmental Hospital (J.G.H) 51 (12%), AL-Razi 
Hospital (R.H) 23 (5%), and the lowest was Palestine Complex (P.M.C) 11(2%), as shown in 
Figure 4.2. 
 
 
 
Figure 4.2: Frequency of abdominal-pelvis CT examinations per hospital. 
 
 
P.A.H 
36% 
J.G.H 
12% 
P.M.C 
2% 
A.H 
24% 
A.I.H 
21% 
R.H 
5% 
P.A.H
J.G.H
P.M.C
A.H
A.I.H
R.H
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4.7.4. EDs and LAR of cancer assessment and data comparisons: 
Data comparison contained three parts. 
 
4.7.4.1. Effective dose assessment: 
ED was estimated by DLP and appropriate normalized coefficients (K) that can be found in 
the European Guidelines on Quality Criteria for CT Report 16262, for abdominal-pelvis CT 
equal 0.015 mSv/mGy.cm (European Commission (EUR) Report 16262, 1995). 
 
ED = K * DLP …………………...……………………………………………………….… (3) 
 
4.7.4.2. The lifetime attributable risk (LAR) of cancer: 
After ED assessment for patients, LAR of cancer incidence and cancer mortality are calculated 
by the following equations respectively with depending on tables that display LAR of cancer 
Incidence and Mortality for adults male and female at age of exposure (APPENDIX C and D) 
(The BEIR VII (2006) report, 2006): 
 
LAR of Cancer Incidence%  
  (   )
   
  
    (                )
      
      ……..………...…… (4) 
    
LAR of Cancer Mortality   
  (   )
   
  
    (               )
      
     ……...…………...... (5) 
 
The effective dose calculations were used for the following comparisons: 
 
1) Total population dose vs. global average comparison. 
To compare total results of ED and LAR of cancer incidence and mortality values for total 
population in this study with previous studies results. 
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2) Private vs. governmental sector comparison. 
To compare effective doses and lifetime cancer risk values from private and governmental 
hospitals.  
 
3) Scanner vs. scanner comparisons (comparison between hospitals). 
To compare EDs and calculated LAR of cancer incidence and mortality values for each 
scanner with other scanners between hospitals.  
 
4.8 Statistical analysis 
 
Dose measurements, which are required for effective dose and the lifetime cancer risk 
assessment, were taken from the display monitor in the CT-scan unit and then, ED was 
assessed per patient by using the previous equations; collected data was used as input to 
Microsoft Excel version 2007. 
 
4.9 Ethical considerations 
 
- The proposal was submitted to Al-Quds University - Faculty of Public Health review 
board to obtain approval and permission to conduct the study. 
 
- Approvals were obtained from the Ministry of Health to conduct the study in the 
governmental hospitals. 
 
- Approvals were also obtained from the mangers of private hospitals, which were included 
in the study, to conduct the study in the private sector hospitals. 
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- Confidentiality of the gathered data was reserved. There were no identifying mechanisms, 
like codes, names, or even numbers, which might trace personal information to any 
specific patient. The study should not present any conflict of interest. 
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Chapter Five 
 
 
Results and Discussion 
 
This chapter outlines the results of the study, ED estimations and applications of ED values for 
lifetime cancer risks incidence and mortality for total population with discussion of the results, 
limitations of the study, recommendations and future study. 
 
5.1 Results 
 
5.1.1. Parameters for abdominal-pelvis CT scans for total population: 
 
Table 5.1 provides a summary of the parameters that affected EDs and LAR cancers risk 
assessment for total study population. 
 
Table 5.1: Parameters of EDs and LAR cancer risk for total population. 
 
No. of 
patients 
Percentage 
(%)/total study 
population 
mAs kVp Scan 
length 
(mm) 
Slice 
thickness 
(mm) 
CTDIv (mGy) DLP 
(mGy.cm) 
435 284.22 120 434.79 2.61 18.06 ± 6 918.26 ± 364.6 13.81 ± 5.4            
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5.1.2. ED and LAR of cancer incidence and mortality for total population: 
 
For the total population, average effective dose was 11.80 ± 5.3 mSv, ranging between 0.50 
and 36.79 mSv, which is in acceptable range of abdominal pelvis CT-dose for adults 
worldwide 
 
The average lifetime attributable risk of cancer incidence in percentage was 0.083 % (1 in 
2107) ranging between 0.001% (1 in 100000) and 0.245 % (1 in408). 
 
While the average lifetime attributable risk of cancer mortality in percentage was 0.049% (1 in 
3164) ranged between 0.001% (1 in 100000) and 0.193% (1 in 518). This is shown in Table 
5.2. 
 
Table 5.2: EDs and LAR of cancer risk incidence and mortality for total population. 
 
No. of 
patients 
ED (mSv) LAR Inc % LAR Mort % 
Average                       Range Average              Range Average                 Range 
435 11.80 ± 5.3              0.50 – 36.79 0.083           0.001- 0.245 0.049              0.001 - 0.193 
 
The average effective dose for abdominal-pelvis CT of this study was 13.81 ± 5.4 mSv. The 
typical global effective doses for abdominal and pelvis CT is about 10 mSv. We found that 
there is a small difference between them, which is shifted toward higher LAR of cancer risk 
incidence, which was 0.097% (1 in 1031), and LAR of cancer mortality was 0.056% (1 in 
1786).  
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5.1.3. Parameters for abdominal-pelvis CT scans per sector: 
 
It was also noted that parameters for governmental sector were higher than those for private 
sector, since ED in private sector were 13 ± 6.7 mSv, 0.090% (1 in 1111), 0.053% (1 in 1887) 
respectively. While these parameters for governmental sector was 14.43 ± 3.8 mSv. LAR of 
cancer risk incidence was 0.103% (1 in 971), and LAR of cancer mortality was 0.063% (1 in 
1587), 
 
Table 5.3 provides a summary of the parameters that affected EDs and LAR cancers risk 
assessment for sectors. 
 
Table 5.3: Parameters of EDs and LAR cancer risk for adult patients for sectors. 
 
Hospital No. of 
patients 
Percentage 
(%)/total 
study 
population 
mAs kVp Scan 
length 
(mm) 
Slice 
thickness 
(mm) 
CTDIv 
(mGy) 
DLP 
(mGy.cm) 
Hospital LAR 
Inc % 
LAR 
Mor % 
Priv. 217 50 249.16 120 460.04 1.62 21.39 ± 7 878.77 ± 444.6 13 ±  6.7 0.090 0.053 
Gov. 218 50 319.11 120 409.64 3.54 19.62 ± 4.3 957.57 ± 257 14.43 ± 3.8 0.103 0.063 
 
5.1.4. ED and LAR of cancer incidence and mortality assessment for patients in sectors: 
 
For private sector (which was equal 50% of the total study population), average effective 
dose was 11.45 ± 6.4 mSv, ranging between 1.77 and 36.79 mSv. The average lifetime 
attributable risk of cancer incidence in percentage was 0.077 % (1 in 1992) ranging between 
0.008% (1 in 12500) and 0.245% (1 in 408). While the average life time attributable risk of 
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cancer mortality in percentage was 0.046% (1 in 3166) ranging between 0.006% (1 in16667) 
and 0.156% (1 in 641). 
 
For governmental sector (which also was equal 50 % of the total study population), average 
effective dose was 12.16 ± 4.1 mSv, ranging between 0.50 and 25.2 mSv. The average lifetime 
attributable risk of cancer incidence was 0.088 % (1 in 2215), ranging between 0.001 % (1 in 
100000) and 0.233 % (1 in 429). While the average life time attributable risk of cancer 
mortality was 0.052 % (1 in 3163) ranging between 0.001 % (1 in 100000) and 0.193 % (1 in 
518), as is shown in Table 5.8. 
 
Table 5.4: EDs and LAR of cancer risk incidence and mortality in percentage for sectors. 
 
Sector No. of 
patients 
ED (mSv) LAR Inc % LAR Mort % 
Average                Range Average            Range Average               Range 
Priv. 217 11.45 ± 6.4     1.77 – 36.79 0.077         0.008 - 0.245 0.046              0.006 - 0.156 
Gov. 218 12.16 ± 4.1       0.50 – 25.2 0.088          0.001- 0.233       0.052             0.001 - 0.193 
 
5.1.5. Parameters for abdominal-pelvis CT scans per hospital: 
 
1. Princess Alia Hospital (P.A.H): 
Princess Alia   Hospital was the most frequent CT examination source during the study 
period with 156 (36%) adult patients, with 79 females and 77 males.  
 
The average tube voltage was 120 kVp, average tube current-time product was 365.9 mAs, and 
mean scan length was 414.6 mm. Slice thicknesses was 3.1 mm. This is shown in Table 5.5. 
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Table 5.5: Average parameters of abdominal-pelvis CT examination in P.A.H. 
 
 
For Princess-Alia hospital (equal 36% of total study population), the average effective dose 
was 12.47 ± 4.3 mSv, ranging between 0.5 and 25.2 mSv. 
 
The average lifetime attributable risk of cancer incidence in percentage was 0.092 % (1 in 
2438) ranged between 0.001% (1 in 100000) and 0.233% (1 in 429). 
 
The average life time attributable risk of cancer mortality was 0.054 % (1 in 3415), ranging 
between 0.001% (1 in 100000) and 0.193 % (1 in 518), as shown in Table 5.6. 
 
Table 5.6: EDs and LAR of cancer risk incidence and mortality in percentage for P.A.H. 
 
Hospital No. of 
patients 
ED (mSv) LAR Inc % LAR Mort % 
Average                    Range Average              Range Average              Range 
P.A.H 156 12.47 ± 4.3        0.5 - 25.2 0.092          0.001- 0.233 0.054      0.001 - 0.193 
 
 
 
Hospital No. of 
patients 
Percentage 
(%)/total 
study 
population 
mAs kVp Scan 
length 
(mm) 
Slice 
thickness 
(mm) 
CTDIv 
(mGy) 
DLP 
(mGy.cm) 
P.A.H 156 36 365.9 120 414.6 3.1 19.81 ± 4.1 831.1 ± 283.4 
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2. Jenin Governmental Hospital (J.G.H): 
Jenin Governmental Hospital is one of the included governmental hospitals; where the total 
number of patients was 51 (12%) adult patients, with 30 females and 21 males.  
 
The average tube voltage was 120 kVp, average tube current-time product was 202.4 mAs, and 
mean scan length was 397.75 mm. Slice thicknesses was 5 mm. This is shown in Table 5.7. 
 
Table 5.7: Average parameters of abdominal-pelvis CT examination in J.G.H.  
 
Hospital No. of 
patients 
Percentage 
(%)/total 
study 
population 
mAs kVp Scan 
length 
(mm) 
Slice 
thickness 
(mm) 
CTDIv (mGy) DLP 
(mGy.cm) 
J.G.H 51 12 202.4 120 397.75 5 20.64 ± 3.3 818.2 ± 191.4 
 
 
For Jeneen Governmental Hospital (which was equal 12% of the total study population), 
average effective dose was 12.27 ± 2.9 mSv, ranging between 6.1 and 17.85 mSv. 
 
The average lifetime attributable risk of cancer incidence in percentage was 0.082% (1 in 1495) 
ranging between 0.023% (1 in 4348) and 0.206% (1 in 485). 
 
While the average life time attributable risk of cancer mortality in percentage was 0.050 % (1 
in 2258) ranging between 0.019 % (1 in 5263) and 0.096 % (1 in 1041), as shown in Table 5.8. 
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Table 5.8: EDs and LAR of cancer risk incidence and mortality in percentage for J.G.H. 
 
Hospital No. of 
patients 
ED (mSv) LAR Inc % LAR Mort % 
Average               Range Average          Range Average            Range 
J.G.H 51 12.27 ± 2.9   6.11 – 17.85 0.082    0.023 - 0.206 0.049     0.019 - 0.96 
 
3. Palestine Medical Complex (P.M.C): 
Palestine Medical Complex is one of the governmental hospitals; where the total number of 
patients was only 11 (2%) adult patients, with 9 females and 2 males.  
 
The average tube voltage was 120 kVp, average tube current-time product was 197.5 mAs, and 
mean scan length was 394.4 mm. Average slice thicknesses was 3 mm. This is shown in Table 
5.9. 
 
Table 5.9: Average parameters of abdominal-pelvis CT examination in P.M.C. 
 
For Palestine Medical Complex (which was 2% of the total study population), average 
effective dose was 7.21 ± 2.7 mSv, ranging between 2.84 and 11.31 mSv. 
 
The average lifetime attributable risk of cancer incidence in percentage was 0.060 % (1 in 
2383) ranging between 0.013 % (1 in 7692) and 0.116 % (1 in 862). 
Hospital No. of 
patients 
Percentage 
(%)/total 
study 
population 
mAs kVp Scan 
length 
(mm) 
Slice 
thickness 
(mm) 
CTDIv (mGy) DLP 
(mGy.cm) 
P.M.C 11 2 197.55 120 394.4 3 12.15 ± 4.2 480.5 ± 177.3 
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While the average life time attributable risk of cancer mortality in percentage was 0.034% (1 
in 3773) ranging between 0.01% (1 in 10000) and 0.061% (1 in 1639), as shown in Table 5.10. 
 
Table 5.10: EDs and LAR of cancer risk incidence and mortality in percentage for P. M.C. 
 
Hospital No. of 
patients 
ED (mSv) LAR Inc % LAR Mort % 
Average           Range Average     Range Average             Range 
P.M.C 11 7.21 ± 2.7          2.84 - 11.31 0.060   0.013 - 0.116 0.034      0.01 - 0.061 
 
4. AL-Ahli Hospital (A.H): 
AL-Ahli Hospital is one of the private hospitals; where the total number of patients was 104 
(24%) adult patients, with 50 females and 54 males.  
 
The average tube voltage was 120 kVp, average tube current-time product was 178 mAs, and 
mean scan length was 456.8 mm. Average slice thicknesses was 3 mm. This is shown in Table 
5.11. 
 
Table 5.11: Average measurements of abdominal-pelvis CT examination in A.H. 
 
Hospital No. of 
patients 
Percentage 
(%)/total 
study 
population 
mAs kVp Scan 
length 
(mm) 
Slice 
thickness 
(mm) 
CTDIv (mGy) DLP 
(mGy.cm) 
A.H 104 24 178 120 456.8 0.8 11.61 ± 4.8 528.4 ± 243.6 
 
For Al-Ahli Hospital (which was equal only 24% of the total study population), average 
effective dose was 7.93 ± 3.7 mSv, ranging between 1.77 and 18.83 mSv. 
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The average lifetime attributable risk of cancer incidence in percentage was 0.050% (1 in 2602) 
ranging between 0.008% (1 in 12500) and 0.129% (1 in 775). 
  
While the average life time attributable risk of cancer mortality in percentage was 0.031% (1 
in 4061) ranging between 0.006% (1 in 16667) and 0.071% (1 in 1408), as shown in Table 
5.12. 
 
Table 5.12: EDs and LAR of cancer risk incidence and mortality in percentage for A.H. 
 
Hospital No. of 
patients 
ED (mSv) LAR Inc % LAR Mort % 
Average          Range Average           Range Average               Range 
A.H 104 7.93 ± 3.7      1.77 - 18.83 0.050            0.008 - 0.129 0.031            0.006 - 0.071 
 
5. Arab Istishari Hospital (A.I.H): 
Arab Istishari Hospital is one of the private hospitals; total number of patients was 90 (21%) 
adult patients, with 20 females and 63 males.  
 
The average tube voltage was 120 kVp, average tube current-time product was 305.2 mAs, and 
mean scan length was 460.5 mm. Average slice thicknesses was 1.8 mm. This is shown in 
Table 5.13. 
 
 
Table 5.13: Average parameters of abdominal-pelvis CT examination in A.I.H. 
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Hospital No. of 
patients 
Percentage 
(%)/total 
study 
population 
mAs kVp Scan 
length 
(mm) 
Slice 
thickness 
(mm) 
CTDIv (mGy) DLP 
(mGy.cm) 
A.I.H 90 21 305.2 120 460.5  1.8  20.44 ± 3.8 950.3 ± 430.3 
 
For Arab Istishari Hospital (which was about 21% of the total study population), the average 
effective dose was 14.25 ± 6.5 mSv, ranging between 3.02 and 36.79 mSv. 
 
The average lifetime attributable risk of cancer incidence in percentage was 0.097% (1 in 1492) 
ranging between 0.019% (1 in 5263) and 0.239 % (1 in 418). 
 
While the average life time attributable risk of cancer mortality in percentage was 0.056% (1 
in 2466) ranging between 0.011% (1 in 9090) and 0.119 % (1 in 840), as shown in Table 5.14. 
 
Table 5.14: EDs and LAR of cancer risk incidence and mortality for A.I.H. 
 
Hospital No. of 
patients 
ED (mSv) LAR Inc % LAR Mort % 
Average                Range Average           Range Average                Range 
A.I.H 90 14.25 ± 6.5    3.02 - 36.79 0.097     0.019 - 0.239 0.056         0.011 - 0.119 
 
6. AL-Razi Hospital (R.H): 
AL-Razi Hospital is one of the private hospitals; total number of patients was 23 (5%) adult 
patients, with 13 females and 10 males.  
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The average tube voltage was 120 kVp, average tube current-time product was 351.9 mAs, and 
mean scan length was 472.9 mm, average slice thicknesses was 5 mm. This is shown in Table 
5.15. 
 
Table 5.15: Average parameters of abdominal-pelvis CT examinations in R.H. 
 
Hospital No. of 
patients 
Percentage 
(%)/total 
study 
population 
mAs kVp Scan 
length 
(mm) 
Slice 
thickness 
(mm) 
CTDIv 
(mGy) 
DLP 
(mGy.cm) 
R.H 23 5 351.9 120 472.9 5 23.04 ± 9.6 1094 ± 480.3 
 
For AL-Razi Hospital (which was equal only 5% of the total study population), average 
effective dose was 16.41 ± 7.2 mSv, ranging between 6.88 and 34.97 mSv. 
 
The average lifetime attributable risk of cancer incidence in percentage was 0.122% (1 in 1187) 
ranging between 0.021% (1 in 4762) and 0.245% (1 in 408). 
 
While the average life time attributable risk of cancer mortality in percentage was 0.071% (1 
in 1856) ranging between 0.018% (1 in 5556) and 0.156% (1 in 641), as shown in Table 5.16. 
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Table 5.16: EDs and LAR of cancer risk incidence and mortality in percentage for R.H. 
 
Hospital No. of 
patients 
ED (mSv) LAR Inc % LAR Mort % 
Average                     Range Average            Range Average               Range 
R.H 23 16.41 ± 7.2       6.88 - 34.97 0.122     0.021 - 0.245 0.071       0.018 - 0.156 
 
5.2 Discussion 
5.2.1. Summary of Parameters for abdominal-pelvis CT scans 
 
Based on hospitals, the highest average EDs values in mSv, were in R.H with (16.41 ± 7.2)    
mSv, A.I.H (14.25 ± 6.5) mSv, J.G.H (12.27 ± 2.9) mSv, P.A.H (12.47 ± 4.3) mSv, while 
P.M.C (7.21 ± 2.7) mSv, A.H (7.93 ± 3.7) mSv. 
. 
Highest average ED in AL-Razi Hospital with 16.41 mSv, may refers to a high value of mAs 
with 351.9 and highest scan length value with 472.9mm, highest slice thickness with 5 mm, 
highest CTDIv with 23.04mGy, and highest DLP with 1094 mGy.cm. 
 
While the Lowest average ED in P.M.C with 7.21 mSv, low value here also may refers to low 
values of mAs with 197 mAs, and lowest scan length with 394.4 mm, moderate slice thickness 
with 3 mm, low CTDIv with 12.15 mGy, and the lowest DLP value with 480.5 mGy.cm. 
 
Whereas the highest value of LAR of cancer risk incidence was also in R.H (0.122%), P.A.H 
(0.092%), A.I.H (0.097%), J.G.H (0.082%), P.M.C (0.060%), and the lowest value in A.H 
(0.050). 
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Based on LAR of cancer risk mortality also because of the highest average ED dose in this 
hospital, the highest value also was in R.H (0.0.071%), P.A.H (0.054 %), A.I.H (0.056%), 
J.G.H (0.050 %), P.M.C (0.034%), and the lowest value in A.H (0.031%). Table 5.17 provides 
a summary of the parameters that for included hospitals.  
 
Table 5.17: Parameters of EDs and LAR cancer risk for adult patients in six hospitals. 
 
Hospital No. of 
patients 
Percentage 
(%)/total 
study 
population 
mAs kVp Scan 
length 
(mm) 
Slice 
thickness 
(mm) 
CTDIv 
(mGy) 
DLP 
(mGy.cm) 
ED 
(mSv) 
LAR 
Inc % 
LAR 
Mor % 
P.A.H 156 36 365.
9 
120 414.6 3.1 19.81 ± 
4.1 
831.1 ± 
283.4 
12.47 ± 
4.3 
0.092 0.054 
J.G.H 51 12 202.
4 
120 397.75 5 20.64 ± 
3.3 
818.2 ± 
191.4 
 
12.27 ± 
2.9 
0.082 0.049 
P.M.C 11 2 197.
55 
120 394.4 3 12.15 ± 
4.2 
480.5 ± 
177.3 
7.21 ± 
2.7 
0.060 0.034 
A.H 104 24 178 120 456.8 0.8 11.61 
± 4.8 
528.4 ± 
243.6 
7.93 ± 
3.7 
0.050 0.031 
A.I.H 90 21 305.
2 
120 460.5 1.8 20.44 
± 3.8 
950.3 ± 
430.3 
14.25 
± 6.5 
0.0.97 0.056 
R.H 23 5 351.
9 
120 472.9 5 23.04 
± 9.6 
1094 ± 
480.3 
16.41 
± 7.2 
0.122 0.071 
 
There is a notable wide variation between CTDIv, DLP, and ED values for six included 
hospitals in Palestine, since the value of CTDIv ranging from 11.61 to 23.04 mGy, and DLP 
values ranging between 480.5 and 1094 mGy.cm, so that ED values ranging between 7.21 and 
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16.41 mSv, four hospitals from six had ED value higher than global value of abdominal-pelvis 
CT which is equal nearly 10 mSv.  
 
CTDIv values for adult patients in the included hospitals are presented in Figure 5.1. The 
values were higher in R.H, J.G.H, A.I.H, and P.A.H. 
 
 
 
Figure 5.1: CTDIv values in the included hospitals. 
 
There is a strong positive relationship between CTDIv and effective doses in the included 
hospital, as it shown in figure 5.2. 
 
 
Figure 5.2: Correlation between CTDIv and effective dose for patients in all included hospitals. 
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DLP values for adult patients in the included hospitals are presented in Figure 5.3. The values 
were higher in J.G.H, R.H and P.A.H; two of them are governmental hospitals. 
 
 
 
Figure 5.3: DLP values for adult patients in the included hospitals. 
 
Average ED values for adult patients in the included hospitals are presented in figure 5.4. The 
values were higher in R.H, A.I.H, J.G.H, and P.A.H. 
 
 
 
 
Figure 5.4: Distribution of average ED values for adult patients in the included hospitals. 
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5.2.2 Relationship between parameters and Effective dose for total population in six 
hospitals in West Bank: 
Figure 5.5 shows correlation between mAs and ED for total study population. Showed strong 
positive relationship between two values. 
 
 
 
Figure 5.5: Correlation between mAs and ED for total study population. 
 
Figure 5.6 shows correlation between scan length and ED for total study population. Increase 
in scan length was associated with increase in average ED value. 
 
 
 
Figure 5.6: Correlation between scan length and ED for total study population. 
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Figure 5.7 shows correlation between CTDIv and ED for total study population. There is a 
strong positive or direct relationship between CTDIv and ED value, trendline shows that any 
increase in CTDIv will be associated with increase in average ED value. 
 
 
 
Figure 5.7: Correlation between CTDIv and ED for total study population. 
 
5.2.3 CT radiation doses comparison between Palestine and other international dose level 
references 
5.2.3.1 Comparison between CTDIv, DLP and effective dose for adult patient’s 
abdominal-pelvis CT in Palestine and other countries: 
 
In comparison with various dose reference levels, Palestine is in acceptable level in CTDIv, 
DLP and effective dose values. Figure 5.8 shows CTDIv in various references, values ranging 
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Figure 5.8: Comparison between CTDIv parameters in various references worldwide. 
 
While figure 5.9 shows DLP in various references ("Cite a Website - Cite This For Me", 
2018), values ranging between 600 to 1000 mGy.cm, while West Bank was 787 mGy.cm. 
 
 
 
Figure 5.9: Comparison between DLP parameters in various references worldwide. 
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Figure 5.10 shows a comparison between the average ED for abdominal-pelvis CT in this 
work with various references international dose reference levels and also with other published 
data for the same procedure. In this figure average ED ranging between 7.1 to 16.7 mSv. The 
differences in these values may be due to differences in CT-scan protocols and scanners types 
or specifications. Generally, our estimated average ED in abdominal-pelvis CT examinations 
was 11.8 mSv, which is lower than the reference doses from European Union (EU) with 15.6 
mSv. 
 
 
 
Figure 5.10: Comparison between average EDs in various references worldwide. 
 
5.2.4. Age dependant EDs and LAR:  
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Figure 5.11: Correlation between Age and ED for total study population. 
 
Figure 5.12 shows correlation between ages with LAR Inc % for total study population. There 
is a positive relationship between ages and LAR Inc % value, so that the lifetime cancer risk 
incidence weakly associated with patient age. Trendline shows that LAR Inc % decrease while 
ages increase. 
 
 
 
Figure 5.12: Correlation between Age and LAR Inc % for total study population. 
 
Figure 5.12 shows correlation between ages with LAR Mor % for total study population. The 
correlation coefficient is 0.102. This is also a weak relationship between ages and LAR Mor % 
value, so that the lifetime cancer risk mortality weakly associated with patient age. Trendline 
shows that LAR Mor % decrease while ages increase.  
 
0
10
20
30
40
0 20 40 60 80 100
ED
 (
m
Sv
) 
Patient's Age (years) 
0
0.1
0.2
0.3
0 20 40 60 80 100
LA
R
 In
c 
(%
) 
Patients Age (Years) 
47 
 
 
 
Figure 5.13: Correlation between Age and LAR Mor % for total study population. 
 
5.2.4.2. Age dependant LAR for adult patients abdominal-pelvis CT in different hospitals 
in the WestBank: 
Correlation between ages and estimated lifetime attributable cancer risk incidence and 
mortality for patients underwent abdominal-pelvis CT in included hospitals is shown in Figure 
5.14 to figure 5.25. The lifetime attributable cancer risk incidence and mortality were 
decreased while ages increases and vice versa. Younger patients have more radiosensitivty 
than adult patients; so that they have more lifetime cancer risk.   
 
 
 
 
Figure 5.14: Correlation between lifetime attributable cancer risk incidences from abdominal-
pelvis CT in P.A.H. 
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Figure 5.15: Correlation between lifetime attributable cancer risk mortality from abdominal-
pelvis CT in P.A.H. 
 
 
 
 
Figure 5.16: Correlation between lifetime attributable cancer risk incidences from abdominal-
pelvis CT in J.G.H. 
 
 
 
 
Figure 5.17: Correlation between lifetime attributable cancer risk mortality from abdominal-
pelvis CT in J.G.H. 
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Figure 5.18: Correrlation between lifetime attributable cancer risk incidences from abdominal-
pelvis CT in P.M.C. 
 
 
 
 
 
Figure 5.19: Correlation between lifetime attributable cancer risk mortalityfrom abdominal-
pelvis CT in P.M.C. 
 
 
 
 
Figure 5.20: Correlation between lifetime attributable cancer risk incidences from abdominal-
pelvis CT in A.H. 
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Figure 5.21: Correlation between lifetime attributable cancer risk mortality from abdominal-
pelvis CT in A.H. 
 
 
 
Figure 5:22: Correlation between lifetime attributable cancer risk incidence from abdominal-
pelvis CT in A.I.H. 
 
 
 
 
 
Figure 5.23: Correlation between lifetime attributable cancer risk mortality from abdominal-
pelvis CT in A.I.H. 
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Figure 24: Correlation between lifetime attributable cancer risk incidence from abdominal-
pelvis CT in R.H. 
 
 
 
 
Figure 5.25: Correlation between lifetime attributable cancer risk mortality from abdominal-
pelvis CT in R.H. 
 
5.2.5. Sex dependant EDs and LAR:  
 
5.2.5.1. Measurements of EDs and LAR based on patient’s Sex for total study population: 
 
Average ED for male patients (53% of the total study population) was little higher than that 
for female (47 % of the total study population) with 13.42, 14.15 mSv respectively, as shown 
in Table 5.18. 
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Table 5.18: Average EDs and LAR Inc and LAR Mort percentages for adult patients 
undergoing abdominal-pelvis CT in total study population based on sex. 
 
Sex ED (mSv) LAR Inc % LAR Mort % 
F 13.42 0.085 0.062 
M 14.15 0.087 0.051 
 
5.2.5.2. Measurements of EDs and LAR based on patient’s Sex for P.A.H: 
Measurements of lifetime attributable cancer risk incidence and mortality from abdominal-
pelvis CT in P.A.H foe female and male patients was shown in fiure 5.25, 26,27,28. 
 
 
 
Figure 5.26: Correlation between lifetime attributable cancer risk incidence for female from 
abdominal-pelvis CT in P.A.H. 
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Figure 5.27: Correlation between lifetime attributable cancer risk mortality for female from 
abdominal-pelvis CT in P.A.H. 
 
 
 
 
 
 
Figure 5.28: Correlation between lifetime attributable cancer risk incidence for male from 
abdominal-pelvis CT in P.A.H. 
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Figure 5.29: Correlation between lifetime attributable cancer risk mortality for male from 
abdominal-pelvis CT in P.A.H. 
 
5.3 Study Limitations  
 
Different limitations affected the quality and how easily we conducted this study. Some 
limitations are related to political conditions in the West Bank. Check points between cities, 
which make the movement between hospitals very difficult, and therefore the study, will need 
a lot of time, effort, and cost.  
 
In data collection stage, we had some difficulties in dealing with radiologists and 
radiographers, because of huge work load and stress during the working day. In addition, 
radiographers may need to delete patient’s records in a very short period, which make it very 
hard to include larger number of patients in the study. Files with missing information 
(especially patient age and/or sex), were excluded from the study, to prevent bias. 
 
5.4 Conclusion 
 
Finally, the estimated average effective dose for adult patients who underwent abdominal-
pelvis CT examinations in this work was acceptable, since it was 11.8 ± 5.3 mSv for the total 
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was 11.45 ± 6.4 mSv for private (50% of total study population) ranged between 1.77 mSv 
and 36.79 mSv, and 12.16 ± 4.1 mSv for governmental (50% of total study population) ranged 
between 0.5 mSv and 25.2 mSv . 
 
Based on hospitals, the highest average EDs values in mSv, were in R.H with (16.41 ± 7.2)    
mSv, A.I.H (14.25 ± 6.5) mSv, J.G.H (12.27 ± 2.9) mSv, P.A.H (12.47 ± 4.3) mSv, while 
P.M.C (7.21 ± 2.7) mSv, A.H (7.93 ± 3.7) mSv. 
 
LAR cancer risk incidence values in hospitals, whereas the highest was in R.H with 0.122 (1 in 
1187) which is low, P.A.H 0.091% (1 in 2463) low, A.I.H with 0.097% (1 in 1493) low, J.G.H 
0.082% (1 in 1495) low, P.M.C 0.060% (1 in 2383) low, A.H 0.050 % (1 in 2602) low. 
 
The highest LAR cancer risk Mortality values in hospitals was in R.H with 0.071% (1 in 1856) 
low, P.A.H 0.054% (1 in 3415) low, A.I.H with 0.056 % (1 in 2466) low, J.G.H 0.050 % (1 in 
2258) low, P.M.C 0.034 % (1 in 3773) low, A.H 0.031% (1 in 4061) low. 
 
5.5 Recommendations 
 
1) Requests for abdominal-pelvis CT-examinations should be done only by qualified 
physicians who have adequate knowledge and awareness about CT-dose and attributed 
lifetime cancer risk or other stochastic and deterministic effects of a high radiation 
exposure. Such requests should be also reviewed by radiologists to make sure the 
examination is needed, since requesting these examinations must depend on ALARA 
principle, diagnosis quality, and patient safety. 
 
2) Devising Guidelines for doctors about necessity of CT and who to judge and balance 
between the risks and benefits, and diagnosis quality, when they must choose CT, and 
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when they must choose one of the alternatives which haven’t or have a low radiation 
dose such as Ultrasound (U/S), MRI or plain X-ray, if possible.   
 
3) Continuous training for physicians, radiologists, and radiographers about CT-dose 
risks and benefits, whom to choose the most suitable modality, and how to optimize 
CT-dose if it is needed.   
 
4) Using Global Dose Management Software is recommended to help in dose analysis, 
quality assurance, and follow-up. 
 
5) Medical engineers and physicists and other CT-scanner specialists must perform 
quality control tests to ensure that machines work effectively with the best quality and 
safety for patients and workers from any excessive radiation dose due to CT-machine 
mechanical problems.  
 
6) National survey can be used as a solution for a large difference between hospitals in 
the average effective dose; results of such survey can establish a national diagnostic 
reference level and protocol for CT-dose optimization for all scanners in Palestine, and 
to check for unnecessary radiation dose and how to eliminate such exposure. 
 
7) Patient him/herself and his/her family should be aware and educated about the possible 
risks and adverse health effects. Efforts should be done to increase people’s knowledge 
on this issue. 
 
5.6 Future study 
 
More studies and researches about this public health problem should be done in Palestine to 
determine the reasons of high CT-doses and the rapid increase of the rate of requesting and 
using CT-scans in the last two years, while there are a global trends and notable intensive 
efforts to decrease this rate by using other medical imaging alternatives. 
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APPENDICES 
APPENDIX A 
 
Table A.1: Parameters of Abdominal and pelvis CT examinations 
ID Age Sex mAs Scan 
length 
T CTDIv DLP ED (mSv) LAR Inc (%) LAR Mor (%) 
 
Princess Alia Hospital 
1 46 M 438 486 3 24.6 1195.56 17.9334 0.11 0.066 
2 28 M 313 471 3 17.5 824.25 12.36375 0.092 0.05 
3 42 F 438 456 3 24.6 1121.76 16.8264 0.144 0.084 
4 72 F 354 389 3 19.3 750.77 11.26155 0.142 0.033 
5 24 F 375 444 3 21 932.4 13.986 0.198 0.094 
6 35 M 494 486 3 27.7 1346.22 20.1933 0.135 0.077 
7 32 M 354 507 3 19.3 978.51 14.67765 0.1 0.056 
8 56 M 383 441 3 12.7 560.07 8.40105 0.044 0.028 
9 23 M 438 453 3 24.6 1114.38 16.7157 0.149 0.079 
10 67 M 354 462 3 19.3 891.66 13.3749 0.052 0.036 
11 54 F 434 399 5 28.1 1121.19 16.81785 0.114 0.075 
12 53 F 313 435 3 17.6 765.6 11.484 0.08 0.052 
13 36 F 438 471 3 24.6 1158.66 17.3799 0.166 0.091 
14 43 F 494 486 3 27.7 1346.22 20.1933 0.17 0.1 
15 28 M 354 486 3 19.3 937.98 14.0697 0.105 0.057 
16 60 F 354 480 3 19.3 926.4 13.896 0.081 0.057 
17 75 M 396 361 3 19.4 700.34 10.5051 0.027 0.021 
18 35 F 354 495 3 21 1039.5 15.5925 0.152 0.082 
19 41 F 375 486 3 21 1020.6 15.309 0.133 0.077 
20 36 M 354 498 3 19.3 961.14 14.4171 0.096 0.055 
21 25 M 375 483 3 21 1014.3 15.2145 0.126 0.068 
22 38 M 396 429 3 19.4 832.26 12.4839 0.082 0.047 
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23 38 M 354 519 3 19.3 1001.67 15.02505 0.099 0.057 
24 73 F 383 429 3 12.7 544.83 8.17245 0.029 0.023 
25 65 M 354 435 3 19.3 839.55 12.59325 0.052 0.036 
26 64 M 383 291 3 12.7 369.57 5.54355 0.024 0.016 
27 30 M 354 291 3 19.3 561.63 8.42445 0.058 0.032 
28 28 F 383 351 3 12.7 445.77 6.68655 0.079 0.039 
29 43 M 354 492 3 19.3 949.56 14.2434 0.09 0.053 
30 42 M 354 483 3 19.3 932.19 13.98285 0.089 0.052 
31 38 M 32 444 3 17.5 777 11.655 0.076 0.044 
32 32 F 313 456 3 17.5 798 11.97 0.123 0.064 
33 28 M 354 459 3 19.3 885.87 13.28805 0.099 0.054 
34 53 F 396 273 3 19.4 529.62 7.9443 0.055 0.036 
35 55 F 250 249 3 14.1 351.09 5.26635 0.035 0.023 
36 40 M 354 249 3 19.3 480.57 7.20855 0.047 0.027 
37 26 M 383 468 3 12.7 594.36 8.9154 0.072 0.039 
38 34 F 383 456 3 12.7 579.12 8.6868 0.086 0.046 
39 40 F 354 414 3 19.4 803.16 12.0474 0.107 0.061 
40 74 M 375 252 3 28.1 708.12 10.6218 0.029 0.022 
41 65 F 250 252 5 14.1 355.32 5.3298 0.027 0.193 
42 66 M 354 477 3 19.3 920.61 13.80915 0.055 0.038 
43 52 F 375 432 3 21 907.2 13.608 0.097 0.062 
44 70 M 283 465 5 14.1 655.65 9.83475 0.034 0.025 
45 77 F 354 333 3 19.3 642.69 9.64035 0.026 0.022 
46 55 M 396 364 3 19.4 706.16 10.5924 0.057 0.036 
47 37 M 313 543 3 19.3 1047.99 15.71985 0.104 0.059 
48 37 F 438 467 3 24.6 1148.82 17.2323 0.162 0.089 
49 67 F 354 414 3 19.3 799.02 11.9853 0.055 0.041 
50 29 F 313 434 3 17.5 759.5 11.3925 0.128 0.064 
51 51 F 396 432 3 19.4 838.08 12.5712 0.091 0.058 
52 39 M 354 480 3 19.3 926.4 13.896 0.091 0.052 
53 69 M 313 495 3 19.3 955.35 14.33025 0.054 0.037 
54 21 M 313 525 3 19.3 1013.25 15.19875 0.144 0.076 
55 56 F 271 447 3 17.6 786.72 11.8008 0.076 0.051 
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56 64 F 271 474 3 19.4 919.56 13.7934 0.071 0.051 
57 50 M 313 504 3 19.4 977.76 14.6664 0.087 0.053 
58 45 M 396 384 3 19.4 744.96 11.1744 0.069 0.041 
59 50 F 438 456 3 24.6 1121.76 16.8264 0.125 0.079 
60 20 F 396 329 3 19.4 638.26 9.5739 0.158 0.073 
61 57 F 313 435 3 17.5 761.25 11.41875 0.072 0.049 
62 33 M 354 365 3 19.3 704.45 10.56675 0.071 0.04 
63 56 M 354 381 3 19.3 735.33 11.02995 0.058 0.037 
64 54 F 438 462 3 24.6 1136.52 17.0478 0.116 0.076 
65 36 F 375 270 3 21 567 8.505 0.081 0.044 
66 64 F 438 462 3 24.6 1136.52 17.0478 0.088 0.063 
67 33 F 354 486 3 19.3 937.98 14.0697 0.142 0.075 
68 49 M 354 492 3 19.4 954.48 14.3172 0.085 0.052 
69 33 M 313 498 3 17.5 871.5 13.0725 0.088 0.05 
70 67 F 354 423 3 19.3 816.39 12.24585 0.057 0.042 
71 67 F 354 414 3 19.3 799.02 11.9853 0.055 0.041 
72 44 F 438 489 3 24.6 1202.94 18.0441 0.149 0.089 
73 51 M 354 438 3 19.4 849.72 12.7458 0.074 0.045 
74 21 F 375 453 3 21 951.3 14.2695 0.227 0.106 
75 21 M 313 288 3 19.3 555.84 8.3376 0.079 0.042 
76 22 M 354 489 3 19.3 943.77 14.15655 0.13 0.069 
77 44 F 438 474 3 24.6 1166.04 17.4906 0.145 0.086 
78 44 F 438 85 3 24.6 209.1 3.1365 0.026 0.015 
79 70 M 354 204 3 19.3 393.72 5.9058 0.02 0.015 
80 34 M 438 486 3 24.6 1195.56 17.9334 0.12 0.068 
81 46 F 313 426 3 17.5 745.5 11.1825 0.089 0.054 
82 38 F 438 459 3 24.6 1129.14 16.9371 0.156 0.087 
83 30 F 313 507 3 17.5 887.25 13.30875 0.142 0.072 
84 29 F 438 447 3 24.6 1099.62 16.4943 0.185 0.093 
85 67 F 383 47 3 12.7 59.69 0.89535 0.004 0.003 
86 52 F 396 435 3 19.4 843.9 12.6585 0.09 0.058 
87 70 M 469 480 5 35 1680 25.2 0.086 0.063 
88 32 F 250 243 3 14.1 342.63 5.13945 0.053 0.027 
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89 76 F 313 441 3 19.3 851.13 12.76695 0.037 0.031 
90 73 M 438 630 3 24.6 1549.8 23.247 0.068 0.051 
91 27 F 383 96 3 12.7 121.92 1.8288 0.023 0.011 
92 77 M 383 26 3 12.7 33.02 0.4953 0.001 0.001 
93 67 M 383 246 3 12.7 312.42 4.6863 0.018 0.013 
94 67 M 383 56 3 12.7 71.12 1.0668 0.004 0.003 
95 32 M 354 444 3 19.3 856.92 12.8538 0.087 0.049 
96 20 F 375 420 3 14.1 592.2 8.883 0.146 0.068 
97 54 M 425 495 3 23.2 1148.4 17.226 0.095 0.059 
98 45 F 313 263 3 17.5 460.25 6.90375 0.056 0.034 
99 55 M 354 444 3 19.3 856.92 12.8538 0.069 0.044 
100 43 M 396 504 3 19.4 977.76 14.6664 0.093 0.055 
101 30 F 396 408 3 19.4 791.52 11.8728 0.126 0.064 
102 62 M 354 492 3 19.3 949.56 14.2434 0.065 0.043 
103 46 F 438 441 3 24.6 1084.86 16.2729 0.13 0.079 
104 36 F 354 429 3 19.3 827.97 12.41955 0.119 0.065 
105 51 M 438 496 3 24.6 1220.16 18.3024 0.106 0.065 
106 36 M 354 474 3 19.3 914.82 13.7223 0.091 0.052 
107 23 M 354 426 3 19.3 822.18 12.3327 0.11 0.058 
108 31 M 354 420 3 19.3 810.6 12.159 0.083 0.046 
109 36 M 313 432 3 17.6 760.32 11.4048 0.076 0.043 
110 37 M 354 438 3 19.3 845.34 12.6801 0.084 0.048 
111 59 M 354 495 3 19.3 955.35 14.33025 0.072 0.046 
112 20 F 396 405 3 19.4 785.7 11.7855 0.194 0.09 
113 38 M 396 462 3 19.4 896.28 13.4442 0.088 0.051 
114 46 F 438 480 3 24.6 1180.8 17.712 0.141 0.086 
115 31 F 375 438 3 21 919.8 13.797 0.144 0.074 
116 79 M 396 126 3 19.4 244.44 3.6666 0.007 0.006 
117 60 M 313 522 3 17.6 918.72 13.7808 0.067 0.044 
118 57 F 250 525 5 14.1 740.25 11.10375 0.07 0.047 
119 33 F 383 507 3 12.7 643.89 9.65835 0.098 0.051 
120 33 F 438 414 3 24.6 1018.44 15.2766 0.155 0.081 
121 69 F 354 432 3 19.3 833.76 12.5064 0.053 0.041 
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122 33 M 438 497 3 24.6 1222.62 18.3393 0.124 0.07 
123 47 M 354 441 3 19.3 851.13 12.76695 0.078 0.047 
124 43 F 383 411 3 12.7 521.97 7.82955 0.066 0.039 
125 39 F 494 369 3 27.7 1022.13 15.33195 0.139 0.078 
126 44 F 375 453 3 21 951.3 14.2695 0.118 0.07 
127 37 F 494 331 3 27.7 916.87 13.75305 0.129 0.071 
128 37 F 313 67 3 19.3 129.31 1.93965 0.013 0.01 
129 27 F 494 393 3 27.7 1088.61 16.32915 0.202 0.099 
130 31 M 354 471 3 19.3 909.03 13.63545 0.093 0.052 
131 40 F 438 407 3 24.6 1001.22 15.0183 0.133 0.076 
132 45 F 313 279 3 17.5 488.25 7.32375 0.06 0.036 
133 48 M 313 426 3 17.5 745.5 11.1825 0.067 0.041 
134 43 M 313 483 3 17.5 845.25 12.67875 0.08 0.047 
135 56 F 425 471 3 23.2 1092.72 16.3908 0.106 0.071 
136 19 M 354 483 3 19.3 932.19 13.98285 0.142 0.074 
137 27 M 354 456 2 19.3 880.08 13.2012 0.102 0.055 
138 36 F 313 516 3 17.5 903 13.545 0.13 0.071 
139 47 F 422 450 5 31.7 1426.5 21.3975 0.168 0.103 
140 32 F 313 435 3 17.5 761.25 11.41875 0.118 0.061 
141 30 M 354 450 3 19.3 868.5 13.0275 0.089 0.05 
142 71 F 313 429 3 17.6 755.04 11.3256 0.044 0.034 
143 48 F 271 520 5 17.5 910 13.65 0.105 0.065 
144 42 F 313 470 5 17.5 822.5 12.3375 0.106 0.062 
145 60 M 354 486 3 19.3 937.98 14.0697 0.069 0.044 
146 33 M 313 465 3 17.5 813.75 12.20625 0.082 0.046 
147 36 M 354 84 2 19.3 162.12 2.4318 0.016 0.009 
148 63 M 313 510 3 19.3 984.3 14.7645 0.066 0.044 
149 38 M 354 480 5 19.3 926.4 13.896 0.091 0.053 
150 59 F 438 258 3 24.6 634.68 9.5202 0.057 0.04 
151 72 F 250 427 3 14.1 602.07 9.03105 0.033 0.026 
152 49 M 313 429 3 17.6 755.04 11.3256 0.068 0.041 
153 49 M 354 441 3 19.3 851.13 12.76695 0.076 0.046 
154 35 F 313 249 3 17.6 438.24 6.5736 0.064 0.034 
71 
 
155 48 F 469 393 3 35.1 1379.43 20.69145 0.159 0.099 
156 53 M 354 462 3 19.3 891.66 13.3749 0.075 0.046 
 
Jeneen Governmental Hospital 
 
157 67 M 190 564 5 13.49 760.836 11.41254 0.044 0.031 
158 62 M 190 214.5 5 18.99 407.3355 6.110033 0.028 0.019 
159 73 F 190 360.5 5 18.99 684.5895 10.26884 0.036 0.029 
160 59 F 190 376.5 5 26.45 995.8425 14.93764 0.09 0.062 
161 47 F 190 408.5 5 18.99 775.7415 11.63612 0.091 0.056 
162 58 F 190 319.5 5 18.99 606.7305 9.100958 0.056 0.038 
163 33 M 190 370 5 18.99 702.63 10.53945 0.071 0.04 
164 39 F 190 410 5 26.45 1084.45 16.26675 0.147 0.083 
165 65 F 190 448.5 5 26.45 1186.283 17.79424 0.089 0.065 
166 43 M 190 405 5 18.99 769.095 11.53643 0.073 0.043 
167 25 F 190 257.5 5 18.99 488.9925 7.334888 0.099 0.046 
168 48 F 190 440 5 18.99 835.56 12.5334 0.096 0.06 
169 62 F 190 311 5 18.99 590.589 8.858835 0.049 0.035 
170 26 M 190 431 5 18.99 818.469 12.27704 0.099 0.053 
171 30 M 190 390 5 18.99 740.61 11.10915 0.076 0.042 
172 54 M 260 447.5 5 26.45 1183.638 17.75456 0.098 0.061 
173 24 F 190 332.5 5 18.99 631.4175 9.471263 0.134 0.064 
174 59 F 190 449 5 18.99 852.651 12.78977 0.077 0.053 
175 80 F 260 450 5 26.45 1190.25 17.85375 0.038 0.034 
176 49 M 190 374.5 5 18.99 711.1755 10.66763 0.064 0.039 
177 45 M 190 485 5 18.99 921.015 13.81523 0.086 0.051 
178 39 F 260 326.5 5 26.45 863.5925 12.95389 0.117 0.066 
179 44 F 190 460 5 18.99 873.54 13.1031 0.108 0.064 
180 33 M 190 488.5 5 18.99 927.6615 13.91492 0.094 0.053 
181 54 M 190 386 5 18.99 733.014 10.99521 0.061 0.038 
182 80 F 190 375.5 5 18.99 713.0745 10.69612 0.023 0.02 
183 63 M 190 485 5 18.99 921.015 13.81523 0.062 0.041 
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184 33 M 190 514.5 5 18.99 977.0355 14.65553 0.099 0.056 
185 70 M 190 448 5 18.99 850.752 12.76128 0.044 0.032 
186 56 F 190 274.5 5 18.99 521.2755 7.819133 0.051 0.034 
187 45 F 190 375 5 18.99 712.125 10.68188 0.087 0.052 
188 35 F 260 450 5 26.45 1190.25 17.85375 0.174 0.094 
189 55 F 190 396.5 5 18.99 752.9535 11.2943 0.075 0.05 
190 52 F 190 425 5 18.99 807.075 12.10613 0.086 0.055 
191 69 F 190 371.5 5 18.99 705.4785 10.58218 0.045 0.035 
192 48 F 190 332.5 5 18.99 631.4175 9.471263 0.073 0.045 
193 20 F 260 280 5 26.45 740.6 11.109 0.183 0.085 
194 43 F 190 397 5 18.99 753.903 11.30855 0.095 0.056 
195 56 M 190 442 5 18.99 839.358 12.59037 0.042 0.042 
196 40 F 260 430.5 5 26.45 1138.673 17.08009 0.151 0.087 
197 65 M 260 443 5 26.45 1171.735 17.57603 0.073 0.05 
198 57 M 260 221 5 26.45 584.545 8.768175 0.046 0.029 
199 50 F 190 340 5 18.99 645.66 9.6849 0.072 0.045 
200 68 F 190 360.5 5 18.99 684.5895 10.26884 0.046 0.034 
201 55 M 190 448 5 18.99 850.752 12.76128 0.069 0.043 
202 62 M 190 409.5 5 18.99 777.6405 11.66461 0.054 0.036 
203 53 M 190 420 5 18.99 797.58 11.9637 0.067 0.042 
204 67 M 260 432 5 26.45 1142.64 17.1396 0.066 0.046 
205 35 F 190 360.5 5 18.99 684.5895 10.26884 0.1 0.054 
206 58 F 190 492.5 5 18.99 935.2575 14.02886 0.087 0.059 
207 21 F 190 455 5 18.99 864.045 12.96068 0.206 0.096 
 
Palestine Medical Complex 
 
208 47 F 294 420 3 17.28 725.76 10.8864 0.085 0.052 
209 39 F 242 427.5 3 14.22 607.905 9.118575 0.082 0.047 
210 37 F 136 237 3 7.99 189.363 2.840445 0.027 0.015 
211 74 M 141 369 3 8.31 306.639 4.599585 0.013 0.01 
212 23 F 58 415.5 3 9.26 384.753 5.771295 0.085 0.04 
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213 56 F 204 441 3 12.01 529.641 7.944615 0.051 0.034 
214 59 F 166 418.5 3 9.74 407.619 6.114285 0.037 0.025 
215 34 F 146 424.5 3 8.57 363.7965 5.456948 0.054 0.029 
216 21 M 163 436.5 3 9.58 418.167 6.272505 0.059 0.031 
217 32 F 288 445.5 3 16.93 754.2315 11.31347 0.116 0.061 
218 64 F 335 302.9 3 19.72 597.3188 8.959782 0.046 0.033 
 
Al_Ahli Hospital 
 
219 60 F 289 444.6 0.6 13.35 593.541 8.903115 0.052 0.036 
220 49 F 206 460.7 0.6 12.44 573.1108 8.596662 0.065 0.041 
221 64 F 227 454.1 1.2 14.27 648.0007 9.720011 0.05 0.036 
222 29 F 207 479.1 0.6 15.99 766.0809 11.49121 0.129 0.065 
223 66 F 276 418.2 1.2 14.51 606.8082 9.102123 0.044 0.032 
224 70 M 244 461.9 0.6 11.25 519.6375 7.794563 0.027 0.019 
225 18 M 142 386.2 0.6 5.73 221.2926 3.319389 0.035 0.018 
226 39 F 172 484.8 1.2 8.55 414.504 6.21756 0.056 0.032 
227 73 M 139 529.2 1.2 10.62 562.0104 8.430156 0.025 0.019 
228 44 F 137 472.7 0.6 5.73 270.8571 4.062857 0.034 0.019 
229 59 M 279 592.6 0.6 10.76 637.6376 9.564564 0.048 0.031 
230 39 F 203 255.8 0.6 7.2 184.176 2.76264 0.025 0.014 
231 59 M 224 551.1 0.6 10.35 570.3885 8.555828 0.043 0.028 
232 61 M 279 551.1 1.2 19.26 1061.419 15.92128 0.076 0.05 
233 76 F 217 433.7 0.6 12.5 542.125 8.131875 0.024 0.02 
234 24 M 258 490.8 1.2 9.69 475.5852 7.133778 0.061 0.033 
235 59 M 156 467.2 0.6 11.93 557.3696 8.360544 0.042 0.027 
236 50 F 220 505.1 1.2 15.18 766.7418 11.50113 0.085 0.054 
237 30 M 166 536.6 1.2 11.46 614.9436 9.224154 0.063 0.035 
238 74 F 234 511.3 1.2 12.08 617.6504 9.264756 0.031 0.025 
239 28 M 105 490.2 0.6 8.03 393.6306 5.904459 0.044 0.024 
240 18 F 152 419.8 0.6 5.62 235.9276 3.538914 0.064 0.029 
241 66 M 279 214.6 0.6 29.89 641.4394 9.621591 0.039 0.027 
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242 75 M 110 170.2 0.6 12.6 214.452 3.21678 0.008 0.006 
243 73 M 200 525.1 0.6 15.44 810.7544 12.16132 0.036 0.027 
244 60 M 120 143.2 0.6 13.74 196.7568 2.951352 0.014 0.009 
245 27 F 227 214.6 0.6 15.7 336.922 5.05383 0.063 0.031 
246 50 M 152 452.6 0.6 10.52 476.1352 7.142028 0.042 0.026 
247 28 M 165 472.1 0.6 11.41 538.6661 8.079992 0.06 0.033 
248 33 M 145 482.8 0.6 7.19 347.1332 5.206998 0.035 0.02 
249 41 M 160 533.6 0.6 12.36 659.5296 9.892944 0.064 0.037 
250 28 M 149 535 1.2 7.5 401.25 6.01875 0.045 0.025 
251 34 M 112 471.2 0.6 7.75 365.18 5.4777 0.037 0.021 
252 48 F 151 533.7 1.2 11.54 615.8898 9.238347 0.043 0.044 
253 38 F 103 499.8 1.2 7.25 362.355 5.435325 0.05 0.028 
254 40 F 122 419.1 0.6 5.64 236.3724 3.545586 0.031 0.018 
255 68 F 224 423.6 1.2 23.07 977.2452 14.65868 0.065 0.049 
256 54 F 258 468.2 0.6 21.59 1010.844 15.16266 0.103 0.067 
257 32 F 269 385.7 0.6 11.81 455.5117 6.832676 0.07 0.037 
258 61 M 279 555.1 1.2 19.26 1069.123 16.03684 0.076 0.05 
259 72 M 241 600.6 0.6 16.67 1001.2 15.018 0.046 0.035 
260 67 F 186 428.7 0.6 8.17 350.2479 5.253719 0.024 0.018 
261 44 M 110 506.1 1.2 7.59 384.1299 5.761949 0.036 0.021 
262 55 F 275 475.3 1.2 19.37 920.6561 13.80984 0.092 0.061 
263 28 M 149 535 1.2 7.5 401.25 6.01875 0.045 0.025 
264 58 M 161 489.3 1.2 16.9 826.917 12.40376 0.063 0.041 
265 20 F 109 429.3 0.6 5.79 248.5647 3.728471 0.061 0.028 
266 34 M 112 471.1 0.6 7.75 365.1025 5.476538 0.037 0.021 
267 38 M 231 562.7 1.2 22.31 1255.384 18.83076 0.123 0.071 
268 65 F 200 436.1 0.6 10.31 449.6191 6.744287 0.034 0.024 
269 49 F 101 420.2 0.6 7.72 324.3944 4.865916 0.037 0.023 
270 59 F 124 409.1 1.2 6.82 279.0062 4.185093 0.025 0.017 
271 75 F 303 484.1 1.2 17.04 824.9064 12.3736 0.039 0.031 
272 25 F 182 496 0.6 6.21 308.016 4.62024 0.063 0.03 
273 49 M 95 108.7 0.6 10.88 118.2656 1.773984 0.011 0.006 
274 46 M 207 486.3 0.6 11 534.93 8.02395 0.049 0.029 
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275 24 M 210 468.3 0.6 10.41 487.5003 7.312505 0.063 0.034 
276 38 F 154 382.1 1.2 9.68 369.8728 5.548092 0.054 0.029 
277 47 M 111 475.3 0.6 6.14 291.8342 4.377513 0.027 0.016 
278 35 F 224 203.7 0.6 14.03 285.7911 4.286867 0.042 0.023 
279 38 F 141 347.6 0.6 9.75 338.91 5.08365 0.047 0.026 
280 61 F 207 472.7 1.2 12.17 575.2759 8.629139 0.049 0.035 
281 58 F 129 433.6 0.6 8.92 386.7712 5.801568 0.036 0.024 
282 61 M 255 553.7 0.6 15.98 884.8126 13.27219 0.063 0.053 
283 25 F 165 526.6 1.2 6.8 358.088 5.37132 0.073 0.035 
284 54 M 154 569.3 1.2 5.79 329.6247 4.944371 0.027 0.017 
285 64 M 79 404.2 0.6 6.04 244.1368 3.662052 0.016 0.011 
286 37 F 109 445.4 0.6 6.71 298.8634 4.482951 0.042 0.023 
287 46 F 275 447.8 0.6 10.16 454.9648 6.824472 0.054 0.033 
288 46 F 127 456.8 1.2 13.33 608.9144 9.133716 0.073 0.044 
289 20 M 91 503.2 0.6 6.96 350.2272 5.253408 0.051 0.027 
290 67 M 286 510.6 1.2 16.08 821.0448 12.31567 0.048 0.033 
291 25 M 62 407.7 0.6 4.74 193.2498 2.898747 0.024 0.013 
292 53 F 207 461.2 0.6 17.85 823.242 12.34863 0.086 0.056 
293 50 F 186 422.2 0.6 21.3 899.286 13.48929 0.1 0.063 
294 35 M 272 523.6 1.2 17.1 895.356 13.43034 0.09 0.051 
295 24 M 151 494.1 0.6 10.45 516.3345 7.745018 0.067 0.036 
296 67 F 200 467.3 1.2 21 981.33 14.71995 0.068 0.051 
297 80 F 107 495.2 0.6 8.18 405.0736 6.076104 0.013 0.012 
298 52 M 192 529.6 0.6 8.87 469.7552 7.046328 0.04 0.025 
299 45 F 89 425.2 0.6 6.81 289.5612 4.343418 0.035 0.021 
300 48 M 229 509.1 0.6 15.84 806.4144 12.09622 0.073 0.044 
301 30 F 172 452.1 0.6 11.9 537.999 8.069985 0.086 0.044 
302 40 M 95 489.3 1.2 5.74 280.8582 4.212873 0.027 0.016 
303 61 F 175 414.2 0.6 13.38 554.1996 8.312994 0.047 0.033 
304 28 F 96 406.7 0.6 7.34 298.5178 4.477767 0.053 0.026 
305 30 F 269 234.2 0.6 11.26 263.7092 3.955638 0.042 0.021 
306 50 F 215 450.6 1.2 20.25 912.465 13.68698 0.101 0.064 
307 30 M 74 436.8 1.2 7.77 339.3936 5.090904 0.035 0.019 
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308 56 F 213 472.1 0.6 10.38 490.0398 7.350597 0.048 0.032 
309 37 M 165 512.2 0.6 8.92 456.8824 6.853236 0.039 0.026 
310 37 M 207 502.1 0.6 10.68 536.2428 8.043642 0.046 0.03 
311 72 M 255 520.2 0.6 10.76 559.7352 8.396028 0.026 0.019 
312 52 M 82 463.2 0.6 6.27 290.4264 4.356396 0.012 0.015 
313 40 F 86 549.4 1.2 4.01 220.3094 3.304641 0.029 0.017 
314 76 M 171 484.1 0.6 12.48 604.1568 9.062352 0.022 0.017 
315 72 M 105 466.2 0.6 12.02 560.3724 8.405586 0.026 0.019 
316 46 F 195 505.6 0.6 13.49 682.0544 10.23082 0.082 0.05 
317 66 F 110 452.4 0.6 15.22 688.5528 10.32829 0.05 0.037 
318 28 M 105 490.2 0.6 8.03 393.6306 5.904459 0.044 0.024 
319 61 M 279 555.1 1.2 19.26 1069.123 16.03684 0.076 0.05 
320 30 M 166 536.6 1.2 11.46 614.9436 9.224154 0.063 0.035 
321 59 M 156 467.2 0.6 11.93 557.3696 8.360544 0.042 0.027 
322 28 M 165 472.1 0.6 11.41 538.6661 8.079992 0.06 0.033 
 
Istishari Arab Hospital 
 
323 32 M 328 510 1.5 21.3 1086.3 16.2945 0.111 0.062 
324 29 M 322 671 1.5 21.1 1415.81 21.23715 0.152 0.084 
325 61 M 349 1071 1 22.9 2452.59 36.78885 0.175 0.115 
326 80 F 269 628 1.5 17.6 1105.28 16.5792 0.035 0.032 
327 27 F 294 474 1.5 19.3 914.82 13.7223 0.17 0.058 
328 28 M 331 512 1.5 21.8 1116.16 16.7424 0.125 0.068 
329 57 M 337 552 1.5 22.1 1219.92 18.2988 0.095 0.061 
330 69 M 315 506 3 20.7 1047.42 15.7113 0.059 0.04 
331 26 M 334 519 1.5 21.8 1131.42 16.9713 0.136 0.073 
332 22 M 342 538 1.5 22.5 1210.5 18.1575 0.167 0.088 
333 35 M 238 166 3 15.7 260.62 3.9093 0.026 0.015 
334 69 F 277 392 1.5 18.2 713.44 10.7016 0.046 0.035 
335 28 F 307 672 1.5 20.1 1350.72 20.2608 0.239 0.119 
336 54 M 324 630 1.5 21.3 1341.9 20.1285 0.111 0.069 
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337 34 M 328 165 3 21.6 356.4 5.346 0.036 0.02 
338 50 F 338 441 1.5 22.3 983.43 14.75145 0.087 0.069 
339 49 M 296 558 1.5 19.4 1082.52 16.2378 0.097 0.059 
340 21 M 169 468 1.5 11 514.8 7.722 0.073 0.038 
341 51 M 321 688 1.5 21.1 1451.68 21.7752 0.126 0.078 
342 27 F 217 141 3 14.3 201.63 3.02445 0.037 0.018 
343 28 M 302 463 1.5 20 926 13.89 0.096 0.057 
344 33 F 317 165 3 20.8 343.2 5.148 0.052 0.027 
345 41 M 349 501 1.5 33.9 1698.39 25.47585 0.164 0.096 
346 24 M 308 515 1.5 20.2 1040.3 15.6045 0.134 0.072 
347 31 M 271 501 1.5 17.8 891.78 13.3767 0.091 0.051 
348 45 M 347 551 1.5 22.9 1261.79 18.92685 0.117 0.07 
349 37 M 229 498 1.5 15 747 11.205 0.074 0.042 
350 61 F 347 141 3 22.9 322.89 4.84335 0.028 0.019 
351 35 F 311 522 1.5 22.5 1174.5 17.6175 0.172 0.092 
352 56 F 332 161 3 21.8 350.98 5.2647 0.034 0.023 
353 49 M 317 517 1.5 20.8 1075.36 16.1304 0.096 0.058 
354 46 M 300 800 1.5 19.7 1576 23.64 0.145 0.087 
355 45 M 347 189 3 22.9 432.81 6.49215 0.04 0.024 
356 41 M 293 499 1.5 28.4 1417.16 21.2574 0.137 0.08 
357 68 M 327 190 3 21.4 406.6 6.099 0.023 0.016 
358 37 M 232 531 1.5 15.1 801.81 12.02715 0.079 0.045 
359 33 M 347 522 1.5 22.9 1195.38 17.9307 0.121 0.068 
360 23 M 331 516 1.5 21.7 1119.72 16.7958 0.149 0.079 
361 37 F 337 191 5 22.2 424.02 6.3603 0.06 0.033 
362 38 F 298 148 3 19.5 288.6 4.329 0.041 0.022 
363 38 F 293 455 1.5 19.2 873.6 13.104 0.121 0.067 
364 50 M 347 523 1.5 22.8 1192.44 17.8866 0.106 0.064 
365 19 M 275 467 1.5 18.2 849.94 12.7491 0.13 0.067 
366 64 M 331 495 1.5 21.8 1079.1 16.1865 0.07 0.047 
367 50 M 339 501 1.5 22.3 1117.23 16.75845 0.1 0.06 
368 21 M 176 490 1.5 11.5 563.5 8.4525 0.08 0.042 
369 46 M 349 490 1.5 22.9 1122.1 16.8315 0.103 0.062 
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370 18 M 219 759 1.5 14.4 1092.96 16.3944 0.174 0.09 
371 66 M 347 498 1.5 33.8 1683.24 25.2486 0.101 0.07 
372 49 M 347 455 1 13.7 623.35 9.35025 0.056 0.034 
373 58 M 320 695 1.5 21.1 1466.45 21.99675 0.112 0.072 
374 62 M 334 564 1.5 22 1240.8 18.612 0.086 0.057 
375 36 M 290 516 1.5 19.1 985.56 14.7834 0.098 0.056 
376 68 M 348 523 1.5 22.9 1197.67 17.96505 0.066 0.047 
377 78 F 338 455 1.5 22.2 1010.1 15.1515 0.038 0.033 
378 60 F 348 529 1.5 22.9 1211.41 18.17115 0.106 0.074 
379 33 M 322 678 1.5 21.1 1430.58 21.4587 0.145 0.082 
380 57 M 323 655 1.5 21.2 1388.6 20.829 0.108 0.069 
381 72 M 325 569 1 21.4 1217.66 18.2649 0.056 0.042 
382 33 M 286 683 1.5 18.8 1284.04 19.2606 0.13 0.073 
383 29 M 300 166 3 19.8 328.68 4.9302 0.035 0.019 
384 52 F 345 470 
 
22.7 1066.9 16.0035 0.113 0.073 
385 55 M 322 170 3 21.3 362.1 5.4315 0.029 0.018 
386 21 F 285 497 1.5 18.7 929.39 13.94085 0.221 0.103 
387 70 M 279 429 1.5 18.3 785.07 11.77605 0.04 0.029 
388 21 F 208 163 3 13.7 223.31 3.34965 0.053 0.025 
389 19 M 326 608 1.5 21.4 1301.12 19.5168 0.199 0.103 
390 45 M 317 381 1.5 20.9 796.29 11.94435 0.074 0.044 
391 24 F 231 597 1.5 15 895.5 13.4325 0.19 0.091 
392 59 M 263 184 3 17.2 316.48 4.7472 0.024 0.015 
393 70 F 278 168 3 18.1 304.08 4.5612 0.019 0.011 
394 58 F 272 488 1.5 17.8 868.64 13.0296 0.08 0.055 
395 46 M 310 202 3 20.4 412.08 6.1812 0.038 0.023 
396 51 M 347 189 1.5 22.8 430.92 6.4638 0.038 0.023 
397 64 F 272 407 1.5 17.8 724.46 10.8669 0.056 0.04 
398 31 M 305 497 1.5 20 994 14.91 0.102 0.057 
399 29 M 300 166 1.5 19.8 328.68 4.9302 0.035 0.019 
400 33 M 324 650 1.5 21.2 1378 20.67 0.139 0.079 
401 34 F 329 577 1.5 21.6 1246.32 18.6948 0.186 0.099 
402 32 F 331 458 1.5 21.7 993.86 14.9079 0.153 0.08 
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403 36 M 299 482 1.5 19.6 944.72 14.1708 0.094 0.054 
404 53 F 333 530 1.5 21.9 1160.7 17.4105 0.121 0.079 
405 41 M 263 176 3 17.3 304.48 4.5672 0.029 0.017 
406 56 F 343 538 1.5 22.5 1210.5 18.1575 0.118 0.079 
407 33 M 266 531 1.5 17.5 929.25 13.93875 0.094 0.053 
408 58 M 346 509 1.5 22.7 1155.43 17.33145 0.088 0.057 
409 60 M 286 607 1.5 18.9 1147.23 17.20845 0.084 0.055 
410 53 M 348 564 1.5 33.9 1911.96 28.6794 0.161 0.1 
411 18 F 234 460 1.5 15.4 708.4 10.626 0.193 0.087 
412 54 M 267 162 3 17.5 283.5 4.2525 0.023 0.015 
 
Al_Razi Hospital 
 
413 54 M 297 485 5 19.6 950.6 14.259 0.078 0.049 
414 23 M 173 483 5 11.3 545.79 8.18685 0.073 0.039 
415 28 M 288 473 5 18.7 884.51 13.26765 0.099 0.054 
416 20 M 364 452 5 23.9 1080.28 16.2042 0.158 0.083 
417 60 F 431 422 5 28.1 1185.82 17.7873 0.104 0.073 
418 22 F 280 447 5 18.2 813.54 12.2031 0.187 0.088 
419 42 F 581 457 5 38.1 1741.17 26.11755 0.224 0.13 
420 20 M 454 562 5 29.7 1669.14 25.0371 0.245 0.128 
421 34 F 468 488 5 30.5 1488.4 22.326 0.222 0.118 
422 32 M 289 502 5 19 953.8 14.307 0.097 0.054 
423 23 M 295 493 5 19.2 946.56 14.1984 0.126 0.067 
424 20 M 161 437 5 10.5 458.85 6.88275 0.067 0.035 
425 70 M 307 425 5 20.2 858.5 12.8775 0.044 0.032 
426 44 M 333 495 5 21.8 1079.1 16.1865 0.101 0.06 
427 55 F 404 475 5 26.5 1258.75 18.88125 0.125 0.083 
428 79 M 230 483 5 15.1 729.33 10.93995 0.021 0.018 
429 67 F 647 434 5 42.6 1848.84 27.7326 0.128 0.096 
430 69 M 464 512 5 30.3 1551.36 23.2704 0.087 0.06 
431 32 F 321 448 5 21.2 949.76 14.2464 0.147 0.076 
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432 22 M 191 482 5 12.4 597.68 8.9652 0.082 0.044 
433 76 F 271 423 5 17.8 752.94 11.2941 0.033 0.027 
434 54 F 688 518 5 45 2331 34.965 0.237 0.156 
435 19 F 156 480 5 10.2 489.6 7.344 0.127 0.058 
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APPENDIX B 
 
Table B.1: Effective dose parameters in abdomen and pelvis CT-examinations for each patient. 
 
 
Worksheet 
 
Patient ID …………..                                 Hospital …………………. 
Age …………………..                               Sex ………………………. 
                             
 Parameter Value 
Tube potential (kVp)  
MAs  
Slice thickness (mm)  
Scan length  
DLP  
CTDIv or CTDIw  
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Table B.2: Effective dose and lifetime cancer risk assessment in abdomen and pelvis CT-
examinations. 
 
 
Pt 
ID 
Pt 
age 
Pt 
sex 
mA
s 
Scan 
lengt
h 
T CTDI
v 
DLP ED 
For 
abd 
ct 
ED 
For 
pelvis 
ct 
ED 
For 
abd& 
pelvis 
ct 
LAR of 
cancer 
incidence 
(%) 
LAR of 
cancer 
mortalit
y 
(%) 
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Table C.1: Lifetime attributable risk of cancer Incidence for adults male.  
 
Age at Exposure All Cancers 
18 1059 
19 1018 
20 977 
21 947.9 
22 918.8 
23 889.7 
24 860.6 
25 831.5 
26 802.4 
27 773.3 
28 744.2 
29 715.1 
30 686 
31 682.2 
32 678.4 
33 674.6 
34 670.8 
35 667 
36 663.2 
37 659.4 
38 655.6 
39 651.8 
40 648 
41 642.3 
42 636.6 
43 630.9 
44 625.2 
45 619.5 
46 613.8 
47 608.1 
48 602.4 
49 596.7 
50 591 
51 580.8 
52 570.6 
53 560.4 
54 550.2 
55 540 
56 529.8 
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57 519.6 
58 509.4 
59 499.2 
60 489 
61 474.4 
62 459.8 
63 445.2 
64 430.6 
65 416 
66 401.4 
67 386.8 
68 372.2 
69 375.6 
70 343 
71 326.1 
72 309.2 
73 292.3 
74 275.4 
75 258.5 
76 241.4 
77 224.7 
78 207.8 
79 190.9 
80 174 
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Table C.2: Lifetime attributable risk of cancer Incidence for adults female  
 
Age at Exposure All Cancers 
18 1813.2 
19 1729.6 
20 1646 
21 1587.9 
22 1529.8 
23 1471.7 
24 1413.6 
25 1355.5 
26 1297.4 
27 1239.3 
28 1181.2 
29 1123.1 
30 1065 
31 1047.1 
32 1029.2 
33 1011.3 
34 993.4 
35 975.5 
36 957.6 
37 939.7 
38 921.8 
39 903.9 
40 886 
41 871.4 
42 856.8 
43 842.2 
44 827.6 
45 813 
46 798.4 
47 783.8 
48 769.2 
49 754.6 
50 740 
51 724.6 
52 709.2 
53 693.8 
54 678.4 
55 663 
56 647.6 
57 632.2 
58 616.8 
59 601.4 
60 586 
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61 568.3 
62 550.6 
63 532.9 
64 515.2 
65 497.5 
             66 479.8 
67 462.1 
68 444.4 
69 426.7 
70 409 
71 389.5 
72 370 
73 350.5 
74 331 
75 311.5 
76 292 
77 272.5 
78 253 
79 233.5 
80 214 
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                                                     APPENDIX D 
 
Table D.1: Lifetime attributable risk of cancer mortality for adults Male.   
 
Age at Exposure All Cancers 
18 547.8 
19 529.4 
20 511 
21 498 
22 485 
23 472 
24 459 
25 446 
26 433 
27 420 
28 407 
29 394 
30 381 
31 380.2 
32 380.2 
33 379.8 
34 379.4 
35 379 
36 378.6 
37 378.2 
38 377.8 
39 377.4 
40 377 
41 375.3 
42 373.6 
43 371.9 
44 370.2 
45 368.5 
46 366.8 
47 365.1 
48 363.4 
49 361.7 
50 360 
51 355.9 
52 351.8 
53 347.7 
54 343.6 
55 339.5 
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56 335.4 
57 331.3 
58 327.2 
59 323.1 
60 319 
61 312.1 
62 305.2 
63 298.3 
64 291.4 
65 284.5 
66 277.6 
67 270.7 
68 263.8 
69 256.9 
70 250 
71 240.3 
72 230.6 
73 220.9 
74 211.2 
75 201.5 
76 191.8 
77 182.1 
78 172.4 
79 162.7 
80 153 
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Table D.2: Lifetime attributable risk of cancer mortality for adults female. 
 
 mortality for adults female 
 
 
Age at Exposure All Cancers 
18 822.8 
19 792.4 
20 762 
21 740 
22 718 
23 696 
24 674 
25 652 
26 630 
27 608 
28 586 
29 564 
30 542 
31 538.5 
32 535 
33 531.5 
34 528 
35 524.5 
36 521 
37 517.5 
38 514 
39 510.5 
40 507 
41 503.2 
42 499.4 
43 495.6 
44 491.8 
45 488 
46 484.2 
47 480.4 
48 476.6 
49 472.8 
50 469 
51 463 
52 457 
53 451 
54 445 
55 439 
56 433 
57 427 
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58 421 
59 415 
60 409 
61 399.8 
62 390.6 
63 381.4 
64 372.2 
              65                             363 
             66 353.8 
67 344.6 
68 335.4 
69 326.2 
70 317 
71 304.3 
72 291.6 
73 278.9 
74 266.2 
75 253.5 
76 240.8 
77 228.1 
78 215.4 
79 202.7 
80 190 
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التصوير فحوصات  عند المرضى الكبار من بالسرطان الاصابةة وخطر فعالتقييم الجرعة الاشعاعية ال
 الطبقي لمبطن والحوض في الضفة الغربية
 
 
  انعيمسميمان داد : ولاء حجازي إع
 
 المشرف : د. حسين المصري
 
 الممخص :
 
 64هناك حوال  المصدر الأكبر للأشعة التي يتعرض لها المرضى خلال تشخيص امراضهم.الماسحات الطبقية تعتبر 
تقريبا  مميسيفرت 10في حالات مثل التصوير الطبقي مثاليا تعطي جرعة مممتصة  جهاز تصوير طبقي في الضفة الغربية.
امامية ) لمصدر. لذلك  -صورة اشعاعية (خمفية  116حيث تعتبر هذه القيمة الطبيعية عالميا هذه الجرعة تعادل ما يقارب 
الآثار  ة الممتصة وتقييم خطر الاصابة بمرض السرطان مدى الحياة باستخدام تقريرهناك حاجة لفحص وتقييم الجرع
روتوكول او آلية لمتحكم في جرعة عمل بب لمتوصية, خلال كل المسوحات الطبقية في فمسطين الحيوية للاشعاع المؤين
   حماية المريض.ضمان المسح الطبقي وبالتالي 
 
شعة الاضافية خرى والتي ربما تعزى الى هذه الألمسرطان او الآثار الصحية العكسية الأضافية تعني خطر ككبر لاشعة االأ
الاشعة الممتصة المعطاة خلال التصوير الطبقي جرعة الهدف الرئيسي من هذه الدراسة هو تقييم من الفحوصات الطبقية. 
 8لهم في لمبطن والحوض  ت طبقيةم عمل فحوصاسنة) والذين ت 1:-:0السرطان مدى الحياة لممرضى الكبار ( وخطر
 جهاز التصوير شاشةمن خلال تقارير  الدراسة بياناتجمع تم حكومية وخاصة في الضفة الغربية. رئيسية مستشفيات 
  .في المستشفيات المختارة شهرينخلال الموثقة  الطبقي
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 بينما ,ميميسفرت 9;.85الى  7.1لمعدد الكمي لمراسة تراوح بين  ميميسيفرت 5.7 ± :.00معدل الجرعة الممتصة كان 
 كان حالات جديدة لمسرطان بين العدد الكمي لمسكان يتراوح بين القميل جدا الى المتوسط, حيثحدوث  معدل خطركان 
ل من ك 0%(;61.1معدل خطر الوفاة من السرطان مدى الحياة كان بينما  ,)8004من كل  0% (4:1.1 معدل ال
  .بين منخفض , والذي يعتبر) 6805
 
 ;9.85الى  99.0لمقطاع الخاص تراوح بين  ميميسيفرت 76.00 ± 6.8معدل الجرعة الممتصة في القطاعات, كان 
. 4.74الى  7.1لمقطاع الحكومي تراوح بين  ميميسيفرت 80.40 ± 0.6معدل الجرعة الممتصة بينما كان  ,ميميسفرت
اقل و  ,ميميسيفرت 06.80 ± 4.9الممتصة  مع رازيمستشفى الفي  كانت اعمى معدل جرعة ممتصة  بالنسبة لممستشفيات,
  .ميميسيفرت 5;.9 ± 9.5 معدلكانت في المستشفى الاهمي بقيمة لها 
 
والأقل كانت  )9:00من كل  0% (440.1 معدلفي مستشفى الرازي ب كان حالات جديدةحدوث  معدل خطربينما اعلى 
في مستشفى  كان خطر الوفاة من السرطان معدل خطراعلى  ,)4184من كل  0% (171.1 معدلبي في المستشفى الأهل
    .)0816من كل  0% (051.1 معدلوالأقل كانت في المستشفى الأهمي ب )87:0من كل  0% (091.1 معدلالرازي ب
 
في هذا العمل كان ضمن لهم معدل الجرعة الممتصة لممرضى الكبار ممن تم عمل فحوصات طبقية لمبطن والحوض 
  ة كانت جميعها منخفضة.خطر الوفاة من السرطان مدى الحياو  حالات جديدةحدوث  معدل خطر .المستوى المقبول
 
